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ABSTRACT 
 
Al-SADEQ, DUAA,W., Masters of Science: June : 2018, Biomedical Sciences 
Title: The Expression of Retinal miRNA Evoked by Hyperglycemia and After 
Adiponectin Treatment in Human Retinal Endothelial Cells 
Supervisor of Thesis: Nasser M. Rizk. 
 
Background: Diabetes mellitus is a chronic metabolic disease resulting in 
microvascular complications including diabetic retinopathy (DR). Adiponectin (ApN) is 
an adipokine hormone, and recent studies demonstrated that ApN could ameliorate 
critical biological process involved in the pathogenesis of DR. Micro-Ribonucleic acids 
(miRNAs) have been documented as novel biomarkers and are increasingly considered as 
molecules with significant modulatory action. Aim:  To characterize the miRNA profile 
and expression in human retinal endothelial cells (HRECs) exposed to hyperglycemic 
conditions (HG) and illustrate the effect of adiponectin on miRNA expression and related 
pathways in HRECs exposed to HG. Methods: HRECs were treated with high glucose 
(30mM) for 96 hours duration followed by adiponectin (30µg/ml) for 24 h.  Total RNA 
was extracted from HRECs. The gene panel array for both adhesion and angiogenesis 
molecules were performed using commercial RT2 Profiler PCR arrays. Furthermore, we 
utilized the small RNA sequencing for microRNA expression profiling of the HRECs. 
Results: HG treatment increases the expression of different well-known adhesion and 
angiogenesis genes as well as predicted miRNAs involved in these pathways, which was 
counteracted by ApN. RNA-Seq for miRNA profiling revealed 13 differentially 
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expressed miRNAs in HRECs exposed to HG. miR-146a-5p was differentially expressed 
in HRECs treated with ApN. Analysis pathway linked the significantly changed miRNAs 
induced by HG to essential pathways such as hypoxia signaling, inflammation, and 
oxidative stress. Conclusion: HG induces expression of various adhesion and 
angiogenesis genes. Using RNA-Seq technology can accurately identify dysregulated 
miRNA profiles in HG retinal cells. MiR-146a was upregulated by adiponectin which 
targets different pathways involved in DR genesis. 
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1. INTRODUCTION 
 
Diabetic retinopathy (DR) is a severe vision-threating disease that results from 
microvascular abnormality due to hyperglycemia (HG) (1). There are two types of DR: 
non-proliferative diabetic retinopathy (NPDR) which is the early stage and proliferative 
diabetic retinopathy (PDR), which is the late stage (1). Since retinal cells have a high 
oxygen demand, hyperglycemia initiates the angiogenesis mechanism to increase blood 
flow in the retina (2). Therefore, the production of the vascular endothelial growth factor 
(VEGF) is augmented (3). The overexpression of VEGF and angiogenesis in retina 
results in the formation of atypical and dysfunctional retinal vessels. These vessels can 
then break and leak blood and fluid in the retinal area. Consequently, this causes macular 
edema, retinal detachment and then vision loss and blindness (4).  
One of the central regulators of angiogenesis and response of endothelial cells to 
VEGF is the micro RNA (miRNA). MiRNAs have been documented as novel biomarkers 
and are considered as molecules with significant modulatory action in many different 
biologic processes (5). These are small non-coding RNA molecules that negatively 
regulate gene expression and therefore play a role in disease processes. Numerous studies 
showed the relationship between miRNA and the regulation of angiogenesis. In a recent 
study, low level of miR-15a in diabetic retina upregulated the expression of VEGF-A in 
retinal cells (6). MiR-15a was identified as a critical regulator of pro-angiogenic as well 
as pro-inflammatory pathways. 
Currently, PDR is treated with surgical interventions and laser treatments. 
However, they are considered as invasive and of limited efficacy (7). Since VEGF 
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production is increased in DR, anti-VEGF therapy has been proven to be effective in 
treating pathologic neovascularization in DR (8). Similar to laser treatments, anti-VEGF 
could be considered aggressive, and its potential effects on the vessel as well as long-
term safety are still under evaluation (9). Adiponectin (ApN) is a natural hormone 
produced in adipose tissue is highly expressed in healthy individuals and could be 
affected by pathological status. For instance, a study reported that ApN concentrations 
were lower in type 2 diabetes patients (10) and that the severity of DR is associated with 
low ApN concentrations indicating its potential role in DR pathogenesis. The data of the 
recent work conducted in our lab demonstrated that ApN could ameliorate critical 
biological process involved in the pathogenesis of DR such as the oxidative stress, barrier 
function, and the inflammatory pathway. Based on this evidence, we hypothesize that 
miRNA could be involved as critical regulators in the pathogenesis and response to 
adiponectin administration. This study aimed to elucidate the involvement of miRNAs in 
the pathogenesis of microvascular complications of the human retinal endothelial cells 
and response to adiponectin using in vitro cell model. This was followed by an analysis to 
explore their gene expression patterns. To reach this goal, we, used RNA-Seq techniques 
with bioinformatics, to screen for miRNA and used an RT-PCR array of angiogenesis 
gene panel to predict the most dysregulated miRNA involved in angiogenesis. Human 
Retinal Endothelial Cells (HREC) were exposed to hyperglycemia conditions for 24 
hours and 96 hours followed by ApN treatment to investigate the profiling and expression 
of miRNAs and functional pathways involved in the pathogenesis of DR.   
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2. LITERATURE REVIEW 
 
2.1 Epidemiology of Diabetic Retinopathy 
Diabetes mellitus (DM) is a worldwide disease that is prevalent in about 180 
million people (11). This disease is characterized by an imbalance between insulin 
production, insulin need and the body’s ability to use the available insulin. Insulin 
hormone is produced by β cells of the pancreas. When β cells are attacked and destroyed 
by the immune system, this results in type 1 diabetes. The etiology of this attack is still 
unknown, yet genetic factors are believed to play a significant role.  In type 2 diabetes, 
the pancreas produces enough insulin. However, there is an insulin resistance caused by 
either a receptor binding problem or a defect in insulin signaling inside the targeted cells. 
Both types result in high glucose in the blood (hyperglycemia). Consequently, maintained 
hyperglycemia leads to altered microvascular function and a broad spectrum of 
irreversible complications such as diabetic neuropathy (12) and DR which is considered 
one of the most DM serious complications (13). 
DR is the breakdown of retinal vasculature due to persistent hyperglycemia (1). It 
is considered the leading cause of blindness and vision impairment among people 
worldwide. DR is ranked as the fifth most common cause of moderate to severe visual 
impairment (14). In 2012 a pooled analysis of 35 population studies estimated that 93 
million people have diabetic retinopathy worldwide and that PDR is prevalent in 7.5% of 
diabetic patients (15). Therefore, screening for DR remains essential for early diagnosis 
and preventing blindness (16). In a recent systematic review aimed to measure the 
prevalence of age-related eye diseases in Iranian population, DR in at least one eye was 
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prevalent in 2.7% of the total participants (17). The prevalence of DR was 2.5% and 
2.8% in men and women respectively. Statistics showed that the difference between 
genders was not statistically significant (18). The highest prevalence of DR was 21.4% 
and was in the age group of 70–74 years. Many studies have been performed and 
estimated that DR is 36.5–93.6% prevalent in type 1 diabetes in the USA and Europe (19-
21). A study conducted in Italy, included 1,321 diabetic patients with DM who were 
examined for DR, showed that DR was prevalent in 26.2% of the participants (22). 
Interestingly, the results showed that DR prevalence was significantly associated with 
diabetes duration. For instance, PDR was more prevalent after 20 years of diabetes. In the 
Middle East and Asian countries, the prevalence of DR in type 2 diabetes has been 
intensively studied since type 1 diabetes has lower incidence in these populations. Most 
of these countries reported the prevalence of DR to range between 12.9–23.0% (23, 24). 
However, Singapore had a higher DR prevalence (33.9%) than other Asian countries 
(25). Moving to Gulf region, Saudi Arabia also reported a high DR prevalence (36.8%) 
(26). 
 
2.2 Pathogenesis of Diabetic Retinopathy 
Hyperglycemia and hypoxia are the primary triggers of changes in retinal blood 
flow (27-29). The Pericytes provide stability for retinal vessels and control the 
proliferation of endothelial cells. In DR there will be a loss of pericytes, increased 
vascular permeability, and endothelial dysfunction (30). Over time, there will be induced-
release of different angiogenic growth factors including VEGF. VEGF has a central role 
in retinal neovascularization and could lead to diabetic macular edema (31). There are 
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three receptors for VEGF, where VEGFR1 is expressed on macrophages and monocytes, 
VEGFR2 is expressed in vascular endothelial cells, while VEGFR3 in lymphatic 
endothelial cells (32). VEGF-A stimulates the proliferation of endothelial cells through 
VEGFR2-induced activation of different pathways. Besides, VEGF-A promotes vascular 
permeability by activating its receptor on the endothelial cells through two principal 
mechanisms: the temporary opening of para-cellular junctions and formation of trans-
cellular pores (33). Still, the signaling transduction pathway is not well understood (34). 
Increased vascular permeability will cause macular edema by loosening the tight 
junctions between the endothelial cells in the capillary’s walls. As the junctions loosen, 
the fluids will leak out into the surrounding area causing retinal tissue to swell. In 
addition, the retina is protected by the inner blood-retinal barrier (BRB). During NPDR, 
BRB breaks-down and blood constituents leak into the eye retina (35). Over time, high 
blood glucose will damage the retinal blood vessels and consequently will result in 
blurred vision. If this condition is left untreated, DR could cause blindness (4).  
DR is classified into two types: NPDR or pre-DR and PDR (36). NPDR is 
characterized by a low number of pericytes surrounding retinal capillaries and thickened 
basement membrane (1). This thickening of basement membrane may lead to the death of 
vascular cell and vessel instability. PDR is the more advanced stage of the disease where 
there will be hypoxia and formation of new fragile blood vessels (37). The leakage of 
these vessels in the vitreous will cloud the vision. Also, retinal detachment could occur 
due to the formation of scar tissue and the development of glaucoma which represent the 
primary cause of worldwide irreversible blindness (38). The buildup of fluid in the front 
part of the eye increases intraocular pressure that can damage the optic nerve (39). In 
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2015, a meta-analysis of 47 pooled studies reported that relative risk of glaucoma is 1.48 
in DM patients compared to those without diabetes (40). Moreover, the increased relative 
risk of glaucoma was positively associated with the diabetes duration (41). 
Hyperglycemia could contribute to both microvascular and macrovascular 
complications due to several biochemical changes and consequently lead to DR (42). 
These changes include the disruption of various metabolites production such as 
inflammatory cytokines, vasoactive agents, growth factor as well as adhesion molecules 
(43). The development of retinal leukostasis, which is the adherence of myeloid-derived 
cells to the retinal endothelium, will cause the secretion of proteolytic enzymes. This will 
result in further damage leading to capillaries occlusion and focal ischemia (44, 45). 
Consequently, all these disruptions will increase the blood flow and vascular permeability 
and finally promote inflammation and pathologic angiogenesis (46).  
Hyperglycemia induces vascular damage through the activity of three major 
pathways: PKC pathway, advanced glycation end product formation (AGE) pathway and 
the hexosamine pathway. These biochemical pathways become activated in the presence 
of an increased level of fructose-6-phosphate and glycolytic metabolites glyceraldehyde-
3-phosphate (47). Once activated several inflammatory and proangiogenic factors 
including VEGF, basic fibroblast growth factor-2 (bFGF), angiopoietins (Ang-2), 
interleukin-6 and tumor necrosis factor (TNF) will be upregulated. In addition, these 
pathways will result in increased inflammation, oxidative stress, and vascular dysfunction 
and eventually increased vascular permeability then occlusion, and local ischemia (48). 
As mentioned previously, ischemia will initiate the angiogenesis in the retinal cells (49). 
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2.3 Diabetic Retinopathy and Angiogenesis 
Angiogenesis is the process of forming new blood vessels from pre-existing 
vessels. Various conditions could trigger angiogenesis such as tissue hypoxia (50). The 
process starts by vasodilation of blood vessels due to nitric oxide and an increase in 
vascular permeability induced by VEGF. Then, separation of pericytes and breakdown of 
basement membrane through the action of matrix metalloproteinases (MMPs) (51). After 
that, endothelial cells will migrate to the site of injury. These cells will proliferate and 
remodel into capillary tubes. Although angiogenesis is an essential biological process, it 
is a feature of various diseases such as cancer, diabetic retinopathy, glaucoma and 
macular degeneration (52, 53). Angiogenesis is considered the fundamental cause of 
more than 70 diseases (54) and DR is an ischemic complication caused by angiogenesis 
in the avascular area of the eye (55). 
 
2.3.1 Signaling Pathways and Molecules Involved in Retinal Angiogenesis 
Retinal angiogenesis is the final common stage of various blinding disorders (56). 
There are different signaling cascades of cellular and molecular processes which are 
involved in angiogenesis and are critical for cell growth and survival (57). Some of these 
pathways, such as Phosphoinositide 3-Kinase (PI3K), produce biological molecules 
which affect angiogenesis of retinal vessels (58, 59). The angiogenic pathway is initiated 
when a growth factor binds to the receptor of tyrosine kinase leading to receptor 
dimerization. Consequently, it activates lipid kinase PI3K which will then convert 
membrane lipid PIP2 to its active form PIP3 (60). As a consequence, this will initiate Akt 
pathway which promotes cell growth via protein synthesis and reduces cellular death by 
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inhibiting FOXO activity (61). The PIK3CA gene, which is a component of the PI3K 
pathway, is positively correlated with the expression of VEGF (62). VEGF protein 
stimulates migration and proliferation of endothelial cells. It promotes vasodilation by 
indirectly stimulating production of nitric oxide which is a potent vasodilator (63). 
However, over-expression of VEGF has been proved to cause diabetic macular edema 
(64). It is produced in the retina at a higher level than average amounts which results in 
the formation of weak and leaky blood vessels (65). 
Increase in ROS level will cause cellular oxidative stress and leads to 
inflammation which is the etiology of most of the diabetic complications (66, 67). There 
is a cross-talk between different biochemical pathways that contribute to DR 
pathogenesis. Hyperglycemia causes an increased flux of Krebs cycle and increases in 
cytosolic Nicotinamide Adenine Dinucleotide (NADH) (68). Consequently, the number 
of electrons will increase in the mitochondria, and more ROS will be produced (69). ROS 
influence the activation of the NF-κB pathway which is activated in inflammation (70).  
In addition, several studies showed that adhesion molecules are upregulated during 
inflammation and have further impact in DR pathogenesis (71, 72). The binding of white 
blood cells to Inter-Cellular Adhesion Molecule 1 (ICAM-1) located on the surface of 
endothelial cells is a characteristic of inflammation. Several stimuli including VEGF and 
oxidative stress increase the expression of ICAM-1 as well as Vascular Cell Adhesion 
Molecule (VCAM) (73). For instance, a study conducted on diabetic mice lacking the 
ICAM-1 gene or its ligand did not develop leukostasis, and there were no pericyte loss, 
degeneration of the capillaries or increased permeability (74). As the number of adherent 
leukocytes increases, more damage will occur to the blood-retinal-barrier (75). A study 
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showed that the breakdown of blood-retinal-barrier and leukostasis significantly 
decreased after administration of leukocyte function-associated antigen-1 (LFA-1) 
antagonist in diabetic rats (76). All these alterations lead to endothelial dysregulation and 
progression of DR.  
 
2.3.2 Angiogenesis Factors 
The expression of various angiogenic factors could contribute to the DR 
pathogenesis. Basic Fibroblast growth factor (bFGF) is a retinal endothelial mitogen that 
stimulates endothelial proliferation cells and promotes macrophage and fibroblast 
migration to the affected area (77). It has been shown that stimulation of angiogenesis by 
FGF2 causes adverse effects, such as atherosclerosis (78). For instance, a study aimed to 
quantitate the level of bFGF in the vitreous of 36 patients with various retinal conditions 
including PDR showed that eight patients had elevated bFGF level, and of these eight 
patients, six had the active proliferative disease (79). Results suggested that vitreous 
specimens from PDR patients had increased bFGF level and this could be evidence of 
active proliferative retinopathy. In another study, researchers aimed to investigate the 
significant role of bFGF and platelet-derived growth factor (PDGF) in proliferative 
vitreoretinopathy (PVR) pathogenesis (80). A total of 38 vitreous specimens were 
included in the study. Results revealed that both cytokines concentrations were elevated 
in PVR. It was concluded that both bFGF and PDGF might be involved in PVR 
pathogenesis. 
Angiopoietins are vascular growth factors that have significant role in the 
processes of angiogenesis (81). Until today there are four known angiopoietins (82). 
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Angiopoietin-1 has a role in promoting endothelial cell survival as well as in stabilizing 
the interaction of endothelial cells with neighboring cells (83, 84).  It has been shown that 
angiopoietin-1 can block the effect of vascular permeability by VEGF in vivo. For 
instance, in a study using diabetic rat model, angiopoietin-1 reduced both blood-retinal 
barrier breakdown and vascular endothelial injury. Also, it suppressed diabetic 
retinopathy development (85). On the other hand, angiopoietin-2 is upregulated by retinal 
ischemia, VEGF, and hypoxia and is expressed in the angiogenic process (86-88). It helps 
in the development and structural maturation of the newly formed blood vessels (89). 
Another growth factor that regulates cell growth and has a significant role in 
angiogenesis is PDGF which is involved in embryonic development, angiogenesis, cell 
proliferation and migration (90). Similar to VEGF, over-expression of PDGF could be 
related to several diseases. For instance, a study conducted in Greece aimed to elucidate 
the correlation between the level of PDGF isoforms in eye’s vitreous with PDR (91). 
Results showed that levels of all PDGF isoforms in vitreous as well as VEGF were 
significantly higher in the PDR group compared to controls. In addition, PDGF-AA and 
PDGF-BB were correlated considerably with PDR severity. In another study aimed to 
investigate the role of PDGF-AB isoform in the angiogenetic process in 23 patients with 
PDR and PDGF-AB concentration was measured (92). Results showed that that PDGF 
growth factor has a vital role in the PDR pathogenesis and a synergistic effect in 
collaboration with other growth factors such as VEGF and tumor necrosis factor alpha 
(TNFα). 
There are two classes of transforming growth factors: transforming growth factor 
alpha (TGFα) and transforming growth factor beta (TGF-β). They activate signaling 
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pathway for cell proliferation, differentiation, and development. Some literature suggests 
that TGF-β1 gene has a role in the development of DR through disrupting angiogenesis 
(93). For instance, a study showed that high TGF-β1 level is found in ischemic retinal 
vein occlusion (94). Netrins are a group of proteins that were first discovered in 
nematode (95). They are involved in axon guidance and vascular development (55). A 
study aimed to examine the role of VEGF and netrin-1 in the pathogenesis of retinal 
angiogenesis where 18 patients, 10 PDR patients, and eight non-PDR patients, were 
included (96). After measuring the level of VEGF and netrin-1 in the vitreous fluid and 
serum of the patients, it was concluded that both, VEGF and netrin-1, were elevated and 
could have a significant role in pathological retinal angiogenesis. Similarly, another study 
proved this conclusion where netrin-1 has been shown to contribute to the angiogenesis 
and inflammatory disease including diabetic retinopathy (55). Increased level of netrin-1 
in the retina has proven to be a pro-angiogenesis factor of retinal angiogenesis under 
hypoxic condition (97). 
 
2.4 MicroRNAs 
2.4.1 Biology of miRNA 
The interest in miRNA has grown exponentially over the last decade, and its role 
in human diseases is being studied intensively. miRNAs have long evaded the attention 
of scientific community because of their small size and how the changes in miRNAs 
expression are correlated with gene expression and involve both biological and 
pathological processes (98). miRNAs are short noncoding RNAs ranges between 18-22 
nucleotide bases. Genes that code for miRNAs are contained in nucleus DNA (Figure 1). 
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MiRNAs are firstly transcribed by RNA polymerase II, and the product is called primary 
miRNA that forms a hairpin loop structure. The double-stranded miRNA will be 
recognized by DGCR8 (DiGeorge syndrome critical region gene 8) protein and with the 
association of DROSHA enzyme; primary miRNA will be cut into smaller precursor 
miRNA (pre-miRNA). Eventually, pre-miRNA will be exported to the cytoplasm by the 
help of Exportin 5 enzyme. Pre-miRNA will then be recognized by Dicer enzyme, 
endonuclease protein, which will cleave the stem-loop and forms a short double-stranded 
miRNA molecule called miR:miR*duplex. Next, an Argonaute protein, Ago II, interacts 
with Dicer to unwind miRNA and one strand will be released (passenger strand) and 
degraded. The remaining strand (guide strand) interacts with Ago II and other proteins to 
form RNA Induced Silencing Complex (RISC). It can be guided to its target to inactivate 
one or multiple genes. miRNA inactivates messenger RNAs (mRNAs) which are 
necessary for translating the genetic information into proteins. This inactivation could be 
cutting the mRNA which will be further destroyed by the cell or by inhibiting the 
translation. In this case, RISC complex prevents the ribosome subunits from binding. In 
both cases, the gene is silenced since mRNA will not be translated into a protein (99). 
miRNAs dysregulation can have critical consequences in the human body and causes 
many diseases such as heart diseases and cancer (100). 
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Figure 1. The biogenesis of microRNA.  
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2.4.2 Functions of miRNA 
To date, there are more than 2,500 reported miRNAs in humans (101). miRNAs 
have a significant role in facilitating many biological processes and pathophysiological 
stress responses by regulating gene expression (102). For instance, miRNAs control a 
wide range of processes in cardiovascular disease such as vascular inflammation, 
electrical remodeling, myocardial remodeling and lipid processing (100). In addition, it 
can act as a biomarker for platelet reactivity (103, 104). A study conducted on zebrafish, 
using knockout gene strategy, revealed the role of miRNA in developmental processes. 
The study concluded the highly expressed miR-430 family members in zebrafish zygotic 
suggesting its role in development and neurogenesis (105). Similarly, another study 
revealed that mir-375 has a role in the secretion of hormones since it was highly 
expressed in the pituitary gland of zebrafish embryos (106). Further, both mir-372 and 
mir-373 target LATS2, which is a tumor suppressor gene, thus inducing tumorigenesis 
(107). These show that miRNAs have a role in physiological as well as pathological 
processes. Therefore, the therapeutic manipulation of miRNA is the future treatment 
choice for several human disorders (108). 
 
2.4.3 MiRNA and Retinal Angiogenesis in Association to Stress in Diabetic Conditions 
Recently, miRNAs have been recognized as factors that control retinal 
angiogenesis (109). For instance, a study conducted by Italian team identified some 
miRNAs that were upregulated in age-related macular degeneration (AMD) patients. 
Results showed that miR-146a, miR-126, miR-34a, miR-27a, miR-23a, and miR-9 were 
upregulated in AMD patients’ serum (110). On the other hand, miR-155 was 
 15 
 
downregulated. Similarly, another study showed that miR-126 level significantly 
decreased in PDR patients’ serum compared to the control group (111). The study 
concluded that there might be an association between miR-126 and the diabetic vascular 
complications, particularly with PDR. Compared toNPDR and controls, the levels of 
miR-181c, miR-21, and miR-1179 were significantly higher in PDR patients’ serum 
(112). Beside upregulation or downregulation of miRNAs, recent studies showed that 
some miRNAs could regulate pathological angiogenesis. For instance, when miR-410 
interacts with 3′UTR of VEGFA mRNA, it could suppress the expression VEGF-A (113). 
Based on this, a study aimed to elucidate the mechanism of miR-410 targeting VEGF-A 
in mice model. The study showed that miR-410 was highly expressed within two weeks 
after birth and suppressed VEGF-A expression (113). This suggests that miR-410 could 
prevent retinal angiogenesis and hence a potential treatment for retinal angiogenesis in 
the future. CD146 is an endothelial biomarker that functions as a co-receptor to VEGF 
receptor 2 and is upregulated during pathological angiogenesis (114). A study showed 
that miR-329 inhibits CD146 and act as a novel negative regulator of angiogenesis (114). 
When CD146 is upregulated, it promotes tube formation and migration of endothelial 
cells. Results revealed that miR-329 reduced pathological angiogenesis in mice by 
suppressing the expression of CD146 on blood vessels. Therefore, it was proposed that 
miR-329 might be a future therapeutic tool to treat angiogenic diseases (114). 
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2.5 Adipokine, Diabetic Retinopathy, and miRNA 
The adipokines are cell signaling proteins which are secreted by adipose tissue. 
They include metabolic regulators, angiogenic proteins and inflammatory mediators such 
as leptin, adiponectin, omentin, retinol, and visfatin (115). A recent study aimed to 
identify the correlation between serum omentin-1 concentrations and the retinal 
circulatory parameters in type 2 diabetic patients showed that omentin-1 concentration 
was positively related to the retinal blood flow (116). The study concluded that increased 
omentin-1 concentrations in plasma might be associated with high retinal blood flow in 
type 2 diabetic patients with early-stage of DR. Another study enrolled 204 diabetic 
patients to evaluate the omentin-1 levels in both serum and vitreous of DR patients (117). 
Patients were divided into four groups: control, without DR, NPDR, and PDR. Results 
showed that PDR patients’ vitreous and serum omentin-1 levels were significantly 
decreased compared to all other groups. In addition, NPDR patients had reduced level of 
vitreous omentin-1 compared to patients without DR. Interestingly; levels of both 
vitreous and serum omentin-1 in the control group was significantly higher compared to 
the three diabetic patients’ groups. It was suggested that development and severity of DR 
are positively correlated with the serum/vitreous omentin-1 ratio (117). 
Adiponectin (ApN) is a novel modulator for vascular diseases and could be 
involved in the pathogenesis of DR (10). For instance; a study aimed to measure the 
concentration of plasma ApN in type 2 diabetic patients and to investigate the existence 
of an association between ApN and the severity of diabetic retinopathy (10). A total of 74 
patients were involved in the study and compared with a control group consisted of 54 
healthy subjects. Results revealed that ApN concentrations were significantly lower in the 
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diabetic patients than in control group. Moreover, there was an association between the 
ApN concentrations and the severity of DR. This suggests that adiponectin could be 
involved in the pathogenesis of DR. Similarly, another study concluded that ApN 
suppresses human coronary artery endothelial cells migration which is stimulated by 
VEGF. This shows that adiponectin may have a regulatory role in vascular processes 
associated with diseases including atherosclerosis and diabetes (118). Other studies 
showed that there is an association between the risk of obesity-related cancers such as 
prostate, breast, and colon cancer and decreased serum ApN levels (119, 120). Since both 
miRNAs and ApN level have a role in DR, the association between them could be studied 
to understand their effect in angiogenesis pathway.  
 
2.6 Current Diabetic Retinopathy Treatment Options 
The current treatment choices for DR are unpleasant, costly and time-consuming 
for the patient (121). One of the current options is laser treatment which uses high 
intensity light. The beam of light is directed into the eye to remove and prevent abnormal 
blood vessels from leaking within the eye (122). Laser treatments for diabetic eye 
diseases can be classified into two types: photocoagulation laser, which is also called 
focal laser treatment, and panretinal photocoagulation (123). Focal laser treatment is the 
standard option to treat diabetic macular edema (124). It slows or stops the abnormal 
blood vessels from leaking in the vitreous. However, the focal laser could also damage 
the healthy retinal tissue (125). Panretinal photocoagulation (PRP), also called scatter 
laser treatment, is one of the options to treat PDR (126). The doctor uses a laser to treat 
the peripheral retina where diabetic changes are causing damage. The procedures cause 
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abnormal blood vessels to shrink and prevent further growth of new blood vessels (123). 
However, more than one PRP procedure may be necessary. Since laser treatments cannot 
restore lost vision, patents should maintain regular eye examination to treat any diabetic 
eye changes as soon as are detected. In addition, laser treatment does not show a 
significant improvement in visual sharpness and does not last for an extended period 
(127). Therefore, other treatment tools were introduced. 
VEGF protein, as mentioned previously, has a central role in the formation and 
healthy growth of blood vessels (3). Overexpression of VEGF causes the formation of 
damaged blood vessels, which leaks fluid into the eye. Anti-VEGF drugs are highly 
effective and target VEGF thus preventing the growth of the abnormal blood vessels 
(128). This decreases fluid leakage in the macula and reduces edema, thus improving 
vision. For instance, recent data suggest that anti-VEGF is an alternative treatment for 
PDR than using PRP (8). Decreased diabetic macular edema (DME) onset rate, less 
peripheral visual field loss and fewer vitrectomies over two years are all benefits of using 
anti-VEGF treatment than PRP laser (1). However, anti-VEGF drugs have a broad effect 
and could prevent the re-growth of healthy blood vessels in the eye (129). It is not the 
best choice of treatment for patients who cannot follow up and comply with regular 
injection regimen to prevent the recurrences of PDR. Moreover, anti-VEGF injections are 
invasive, and only 50% of DME patients respond effectively to the treatment (1). 
Long-acting steroids are some of the potential diabetic eye treatments that have 
been used for DR induced by macular edema (130). Corticosteroids target the 
inflammatory cascade and show a significant improvement in vascular complications 
(131). However, this treatment is associated with limitations and adverse events including 
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a high incidence of cataracts and increased intraocular pressure (132). Most of the 
currently available therapies, including these mentioned previously, are invasive and may 
be failleading to blindness in the advanced stage (133). Therefore, new treatment choices 
are required for the early stage of DR. It was proven that ApN, among the adipokine 
family, has a role in regulating the retinal circulation (134). A recent study showed the 
significant effect of adiponectin in counteracting the effect of hyperglycemia and 
reducing the pathophysiological progression of DR (135). It improved the barrier 
dysfunction of retinal cells and reduced apoptosis, ROS production, and leukocyte 
adhesion in adiponectin-treated cells compared to hyperglycemic HRECs. Therefore, the 
effect of adipokines, especially adiponectin, in improving the altered retinal 
microcirculation could prevent the development and progression of DR. 
Several mechanisms and pathways are involved and cause diabetic retinopathy. 
Therefore, we hypothesize that miRNAs may contribute to the pathogenesis of DR. The 
primary goal of this study is to portray the effect of ApN on miRNA expression using 
angiogenic gene panel, and related molecular pathways in HREC exposed to 
hyperglycemia. Further, to correlate such specific miRNA with the biological process 
involved in DR.  
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3. SIGNIFICANCE, HYPOTHESIS AND OBJECTIVES 
 
The current research is significant as it helps to increase our knowledge about the 
role of miRNA in the pathogenesis of DR as well as the changes in HRECs exposed to 
diabetic conditions. This, in turn, could aid the development of a novel therapeutic 
approach for diabetic retinopathy. Understanding the role of miRNAs may help to 
identify new biomarkers to be used for DR diagnosis. One of the main challenges in 
developing therapy is that one miRNA has multi targets and one transcript is regulated 
post-transcriptionally by many epigenetic phenomena, such as methylation, and multiple 
miRNAs (5, 136).  
Here we have identified that ApN could improve the endothelial dysfunction of 
HREC exposed to diabetic conditions in vitro. Therefore, we propose the identification of 
small regulatory molecules like miRNA that is differentially expressed in chronic 
hyperglycemia and altered by adiponectin treatment could help in understanding the 
pathogenesis of HG-induced endothelial dysfunction and pathways involved in such 
mechanisms and how can ApN improve such abnormality. We hypothesize based on 
previous data on HREC exposed to adiponectin, that ApN in a dose of 30ug/ml, could 
ameliorate the endothelial dysfunction of HREC exposed to hyperglycemia via different 
mechanisms. These mechanisms include: reduction of oxidative stress, anti-apoptotic, 
anti-inflammatory, reduction in nitric oxide production, reduce adhesion molecules such 
p-selectin and improve the barrier function (135). To test this hypothesis, we screened for 
the well-known angiogenesis and adhesion gene panels. Data obtained from the screening 
assay would help in the identification of the most significant miRNA involved in DR 
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pathogenesis.  Furthermore, we used the advanced technology of small RNA sequence 
analysis to portray all miRNAs significantly changed in hyperglycemia and its 
perturbations after adiponectin application. Such RNA-sequence gave the chance to 
detect all possible miRNA using the latest version 22 of miRNA base, and not only 
selected specific panels as utilized in microarray chip techniques. Following that, we used 
the bioinformatics as a tool, to search for the targets (genes, and pathways) for that 
significant differentially expressed miRNA to highlight its role in DR pathogenesis. 
 The objectives of the study are the followings: 
1- Screen for the genes and miRNA expressed in high glucose condition 
compared to normoglycemic state using in vitro model of HRECs. In 
subsequent experiments, exposure to glucose could be of short duration and 
long duration to portray and detect any change in the gene panels and predicted 
miRNA. 
2- Screen genes and miRNA in hyperglycemic cells treated with adiponectin as a 
therapeutic tool to ameliorate the genesis of DR as shown in previous data. 3- 
Analyze the selected differentially expressed miRNA and evaluate their role by 
in Silico analysis to indicate its functional roles through analysis of the 
significant pathways involved in DR pathogenesis. 
Gathering data from these objectives could help to answer the research question of the 
current study.  
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4. MATERIAL AND METHODS 
 
4.1 Material and Reagents 
In the current study, four different HRECs vials were used, representing different 
biological samples. Reagents used in the study are shown below in (Table 1).  
 
 
 
 
Table 1: List of reagents used in the study 
 
Item Company Catalogue number 
Human Retinal Microvascular 
Endothelial Cells (HRMECs) 
passage  
Cell System Corporation Cat#ACBRI 181 
Complete Classic Medium Kit with 
Serum 
Cell System Corporation 4Z0-500 
Culture Boost Cell System Corporation 4CB-500 
Complete Serum-Free Medium Kit 
with RocketFuel 
Cell System Corporation Certificate No: SF-
4Z0-500-R 
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CSC Attachment Factor Cell System Corporation 4Z0-210 
CSC Passage Reagent Group™ Cell System Corporation Certificate No: 4Z0-
800 
CSC Cell Freezing Medium Cell System Corporation Certificate No: 4Z0-
705 
BAC-OFF® ANTIBIOTIC 
TONIC  
Cell System Corporation 4Z0-644 
Trypan Blue stian (0.4%) Gibco (Life Technologies) 15250-061 
TRIZOL® reagent Thermo Fisher Scientific, 
Waltham, Massachusetts, 
United States 
Ref No: 15596026 
Phosphate Buffered Saline (PBS) 
pH 7.4 
Gibco (Life 
Technologies) 
10-010-023 
Glucose (5 and 30 mM) Sigma G-7021 
Human gAcrp30/Adipolean Peprotech 450-21-500UG 
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Table 2: List of kits 
 
Item Company Catalogue number 
   
mirVana miRNA Isolation Kit 
 
Thermo Fisher 
 
AM1560 
 
miRNeasy Mini Kit Qiagen 217004 
High capacity RNA- to- cDNA kit Applied Biosystems by 
thermos fisher scientific 
4387406 
Agilent RNA 6000 Nano Kit 
 
Agilent Technologies, 
Waldbronn Germany. 
5067-1511 
RT2 SYBR® Green ROX qPCR 
Mastermix 
QIAgen 330520 
TaqMan™ Gene Expression Master 
Mix 
Applied Biosystems by 
thermos fisher scientific 
4369016 
Extracellular Matrix and Adhesion 
Molecules RT2 Profiler PCR Array 
QIAgen PAHS-013Z 
Angiogenesis RT2 Profiler PCR 
Array 
QIAgen PAHS-024Z                                                                                                                                                                                                                                                                                          
Human Cytokine/Chemokine 
Magnetic Bead Panel 96 Well Plate 
Assay 
Millipore HCYTOMAG-60K-
PX29 
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Table 3: List of instruments 
 
Item Company Cataloug number 
   
The Invitrogen™ Tali™ Image-
based Cytometer 
Life Technologies 
Corporation, USA. 
T10796 
NanoQuant Plate on TECAN 
Infinite 200 PRO microplate 
reader. 
Life sciences, Switzerland Infinite 200 PRO 
NanoQuant 
Thermocycler (Gene Amp®, 
PCR System 9700) 
Thermo Fisher - 
2100 Bioanalyzer system Agilent Technologies, 
Waldbronn Germany 
G2943CA 
Mi-Seq Systems Illumina SY-411-9001DOC 
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Table 4: List of softwares 
 
Item Company 
GraphPad Prism 7 GraphPad Software, Inc. 
FastQC Babraham Bioinformatics 
DEseq2 Bioconductor 
xMAP® Technology Luminex Corporation 
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4.2 Study Design 
 
 
Figure 2: Study Design and workflow 
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4.3 Methods 
4.3.1 Human Retinal Endothelial Cells Cell Culture 
Cryopreserved passage 3 HRECs were rapidly thawed in a water bath at 37°C; 
then complete classic media was immediately added and centrifuged for five minutes 
at 1000 rpm. Cells were then plated in the flask after the addition of complete media 
with one ml of antibiotic Pen-Strep and incubated in 5% CO2 incubator at 37°C until 
confluency. After 24 hours of growth, the media was changed followed by every 48 
hours afterward. The cells were grown and passaged till P5-P6 and then used for the 
study to minimize variability. 
Cell count was performed before culturing or sub-culturing HRECs using Trypan 
Blue. A volume of 10μl cell suspension added in to 10μl of Trypan Blue, and 15μl of 
this mixture was loaded on to hemocytometer and counted under a microscope. Cells 
were counted in the middle square as well as the four corner squares, and the below 
formula was used to retrieve the total number of cells: 
(Total number of cells counted / 5(number of squares)) × 2(dilution factor) 
×10,000 
The cells have also been counted using Tali™ Image-based Cytometer. In the current 
study, at least three biological replicates with three independent experiments were 
conducted. 
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4.3.2 HRECs Treatment 
 
 
 Table 5: Groups treatment and duration. Abbreviations: s refers short exposure 24 hours, 
and l refers to long exposure for 96 hours 
 
 
  
Group Treatment Treatment Duration 
NG-s Normal media (5mM glucose) 24 hours 
HG-s Media with 30mM glucose 24 hours 
HG+ApN-s Media with 30mM glucose and 
30µg/ml  of adiponectin 
24 hours 
ApN-s Normal media (5mM glucose) with 
30µg/ml  of adiponectin 
24 hours 
NG-l Normal media (5mM glucose) 96  hours 
HG-l Media with 30mM glucose 96  hours 
HG+ApN-l Media with 30mM glucose with 
30µg/ml  of adiponectin 
96  hours 
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Cells were grown on a 6 well plate in complete classic media was changed after 
24 hours of growth then by every 48 hours thereafter. Upon 75-85% of cell 
confluency, HRECs were serum starved by replacing the complete classic media with 
serum-free media for 6 hours. Then, HRECs were treated with different treatment 
groups for 24 and 96 hours. Group one is the Normal Glycemia/Control (NG) which 
contained standard complete media and 5 mM of glucose. Group two is high glucose 
(HG) where D-glucose to a final concentration of 30mM was added to regular 
complete media. Group three is high glucose, and adiponectin (HG+ApN) where D-
glucose (30mM) and ApN (30µg/ml) were added to the complete conventional media. 
The last group is ApN (30µg/ml) was added to the normal complete media for 24 h. 
Experiments were performed with three technical replicates for each group of three 
different biological replicates. The following groups were studied after 24 hours and 
96 hours of exposure to, normal glucose and high glucose followed by ApN 
administration for further 24h. 
 
4.3.3 Gene Expression Analysis 
4.3.3.1 RNA Extraction 
Total RNA was extracted from treated HRECs using miRNeasy Mini Kit, Qiagen. 
Briefly, cells in each well were homogenized in 700µl with QIAzol lysis reagent. 
Cells were then incubated for 5 minutes at room temperature then transferred to 
microcentrifuge tubes. A 140μl total volume of chloroform was added to each 
microcentrifuge tube and was shaken vigorously. Microcentrifuge tubes were then 
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incubated for 3 minutes followed by centrifugation at 12000xg for 15 minutes at 4oC. 
Afterward, the aqueous layer was recovered in new 1.5 ml Eppendorf tubes. A 1.5 
volume of 100% ethanol was added to each tube and mix thoroughly. Then, samples 
were transferred to an RNeasy Mini spin column and centrifuged at ≥8000xg for 1 
minute at room temperature. Series of washing steps were followed as instructed by 
the kit manual. After that, 60µl of RNase-free water was used to elute the RNA. 
Finally, RNA was quantified at absorbance 260/280 nm using NanoQuant Plate on 
TECAN Infinite 200 PRO microplate reader. The quality of RNA was measured 
using the 2100 Agilent Bioanalyzer. 
For miRNA extraction, mirVana™ miRNA Isolation Kit was used where the 
sample was lysed in a denaturing lysis buffer that inactivates RNases and stabilizes 
the RNA. Acid-Phenol: Chloroform was used to extract the lysate and removes most 
of the debris and cellular components. This resulted in semi-pure RNA sample that 
was purified using glass-fiber filter. RNA was washed several times and then eluted 
in a low ionic strength buffer 
 
4.3.3.2 cDNA Preparation 
High Capacity RNA to cDNA kit was used to convert the RNA to cDNA. A 
1000ng of total extracted RNA was used in this process. The reaction mixture 
consisted of a total volume 20µl with the following volumes of each component per 
reaction: 10μl of 2X RT Buffer, 1.0μl of 20X Enzyme Mix, up to 9μl RNA sample 
and quantity sufficient to 20μl Nuclease-free water. Reverse transcription reaction 
was performed using Thermocycler (Gene Amp®, PCR System 9700) according to 
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the following cycles: incubation at 37oC for 60 minutes, stopping the reaction by 
heating at 95oC for 5 minutes followed by a hold stage at 4oC. 
4.3.3.3 Quantitative Real-time PCR 
Quantitative RT-PCR was achieved using Applied Biosystem 7500 Real Time 
PCR system to quantitate gene expression using TaqMan Gene Expression Master 
Mix (Applied Biosystem, USA). A total volume of 10μl of reaction mixture consisted 
of different components as shown in Table 4.1. 
 
 
 
Table 6: RT-PCR Reaction Mix 
 
Component Volume per reaction (μL) 
2x Master Mix 5 
20X Primer 0.5 
Nuclease-free water 0.5 
cDNA sample 4 
Total 10 
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Table 7: Oligonucleotide sequences used in RT-PCR 
Gene Primer Sequence 
VEGFA IDT (Hs.PT.56a.1149801.g) 
ADIPQR1 Hs01114951 
ADIPQR2 Hs0022610 
β-actin Hs99999903 
 
4.3.3.4 RT2 Profiler PCR Arrays 
RT2 Profiler PCR Arrays are a 96-well plate that includes preloaded SYBR 
Green-optimized primer of the pathway and disease-specific gene panel. Using the 
RT2 Profiler PCR array allows obtaining highly reliable and accurate expression 
analysis of the desired panel. In addition, RT2 Profiler PCR Arrays can be modified to 
contain a specific panel of genes of interest tailored to the specific research interests 
(137). 
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Table 8: RT2 Profiler PCR Arrays Reaction Mix 
 
Component Volume (μL) 
2x RT2 SYBR Green Mastermix 1350 
Nuclease-free Water 1248 
cDNA sample 102 
Total 2700 
 
 
 
In this study, both human angiogenesis and extracellular and adhesion molecules 
PCR arrays were used to study the angiogenesis and adhesion genes in HRECs 
exposed to HG and thereafter by adiponectin treatment. The Human angiogenesis RT² 
Profiler PCR Array includes 84 genes related to angiogenesis. It also includes 
receptors, growth factors, adhesion molecules, chemokines as well as proteases and 
their inhibitors that have a role in the angiogenesis process. Similarly, the Human 
Extracellular Matrix and Adhesion Molecules RT² Profiler PCR Array profile 84 
genes involved in cell-cell and cell-matrix interactions (138). Adhesion molecules 
play a role in attaching the cells to glycoproteins and proteoglycans to maintain the 
cell shape, structure, and function. Under the normal physiological condition, the 
extracellular matrix (ECM) is involved in cell growth, division, differentiation, and 
migration. However, pathological conditions result in remodeling of ECM and 
changes in the expression of cell adhesion molecules on the cell surface (139). 
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Human Extracellular Matrix and Adhesion Molecules RT² Profiler PCR Array 
contain a variety of ECM proteins such as matrix and metalloproteinases, basement 
membrane constituents, integrins, selectins, cell-adhesion molecule family members, 
and cytoskeleton bridging proteins such as catenins. The gene list of both human 
angiogenesis and adhesion molecules arrays are listed in Appendix 3. 
 
4.3.4 Multiplex ELISA by Luminex 200™ 
Cytokines are a group of soluble proteins that mediate the communication 
between cells and regulate their activities (140). They also regulate a wide range of 
processes such as hematopoiesis, proliferation, and inflammation. Therefore, measuring 
cytokine concentrations is a fundamental approach to study these processes and can be 
used as a diagnostic tool for infection (141). Luminex technology is based on multiple 
analyte profiling using microsphere beads that are 5.6 microns (142). Each micro-bead 
has specific dye concentration resulting in the unique spectral signature which allows for 
identification. Therefore, several bead sets can be combined within the assay allowing for 
multiplexing up to 100 tests in a single reaction volume. The surface chemistry of the 
micro-beads allows chemical coupling of capture reagents such as oligonucleotides, 
receptors, antibodies or peptides. Assays are carried out in 96-well plate with up to 100 
tests per well. Based on the principle of flow cytometry, high-tech fluidics will cause the 
suspended micro-beads to line up in a single file prior passing through the detection 
chamber. Therefore, each micro-bead will be measured discretely. Multiplexed results are 
detected using Luminex system. In the present study, Luminex was used to identify 
specific cytokine, IL-6, involved in inflammatory response. 
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Briefly, 96-well plate was washed with 200µl wash buffer and incubated 10 
minutes on a shaker to clean all wells. Standard with different concentrations, control, 
and samples was then added to wells. Each bead vial contains specific marker/analyte of 
interest that need to be detected. A 150µl from each vial was added to a mixing bottle 
with the addition of 2550µl bead diluent in order to reach a total volume of 3000µl. 
Adding multiple conjugated beads to each sample helped in obtaining multiple results per 
sample. Beads were mixed well then pipetted (25µl) in each well with 25µl of the culture 
supernatant (conditioned media) and incubate at 4oC overnight on shaker 500-700rpm. 
Next day the plate was washed without discarding or losing the beads. This is achieved 
by using a magnetic holder that will attract all beads and prevent their loss while 
washing. Conjugate was then added and incubated on a shaker for 1 hour at room 
temperature. This was followed by addition of Streptavidin-Phycoerythrin incubation for 
30 minutes at room temperature. In order to remove unbound antibodies, the plate was 
placed on the magnetic holder and then washed three times. A total volume of 150 µL of 
Sheath Fluid was added and then the plate was run on Luminex 200™. Results were 
calculated by Xpotent 3.1 software and expressed in pg/ml. This technology reduces 
time; cost and labor effort compared with other traditional methods and has high 
sensitivity and specificity (143). 
  
 37 
 
4.3.5 Library Preparation and miRNA Sequencing 
Before sequencing it is crucial to examine the RNA quality, so as RNA degrarded  
not interfere with the results. A total of 1µg of total RNA was used to generate the NGS 
Library. miRNA was extracted from total RNA and library was prepared using 
NEXTflex Small RNA-Seq Kit v3 (BiooScientific). The adapter was ligated to both ends 
of the miRNA fragments followed by reverse transcription to cDNA. Adaptors are 
essential in this process since they hybridize complementary primers in the cDNA reverse 
transcription and hybridize to flowcell oligos prior bridge amplification during the 
sequencing process. Each library was quantified and run for quality control using the 
Agilent Bioanalyzer High Sensitivity Kit in order to avoid over clustering while 
sequencing. In addition, each library was normalized to 2nM, to ensure that the pool has 
an equal representation of each library. Then an equal volume of each normalized library 
was pooled into one tube for final loading into the Illumina MiSeq instrument. The 
adaptor sequence will hybridize with the oligonucleotides on the surface of the flow cell. 
DNA polymerase, as well as particular nucleotides with fluorescent terminator caps, will 
be added to the flow cell too. DNA polymerase will add only one nucleotide with 
fluorescent terminator cap each round. Once nucleotide added, fluorescent emitted will 
be detected by a camera and store the data as reads. Library preparation, quantification, 
barcoding as well as miRNA sequencing were conducted at Weill Cornell Medicine-
Qatar. 
 Different bioinformatics softwares were used to assess the miRNA sequence as 
shown in the workflow (Figure 2). These include FastQC for quality control, SHRiMP 
for aligning the reads, and R package for analyzing the results and differential gene 
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expression analysis. Target genes of differentially expressed miRNAs and related 
pathways were identified using the gene ontology and KEGG pathway analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Workflow of miRNA sequencing analysis 
 
miRNAseq read files 
(.fastq.gz) 
Quality Control 
FastQC 
Adapter Trimming  
cutadapt 
Read Alignment 
SHRiMP 
Reference Genome: miRBase22 version (hsa) 
Mature Count Extraction 
R package: GenomicAlignments (findOverlaps function) 
PCA for Group Analysis 
R package: prcomp, ggplot2 
miRNA Differential Expression Analysis 
R package: DESeq2 
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4.3.6 Statistical Analysis 
For in vitro studies, each experiment was independently repeated three times from 
three different biological samples. Therefore, values in the figures are expressed as the 
mean of the experiments with standard deviation. Group differences were evaluated using 
ANOVA followed by Tukey’s post hoc test for multiple comparisons. For all analyses, 
two-tailed P < 0.05 was considered sufficient to reject the null hypothesis. Statistical 
analyses were conducted using GraphPad 7 for Windows (Version 6 software; San 
Diego, California) and Microsoft Excel 2013 (Microsoft Corp., Redmond, WA). For 
differential expressed miRNA, the cut off value for p-value was 0.005, and the -2 log fold 
change to 2 was selected.  
  
 40 
 
5. RESULTS 
 
5.1 Cell Viability and Treatment 
Cell morphology, viability, and count were monitored to study the effect of 
hyperglycemia on HRECs and adiponectin administration on the hyperglycemic HRECs. 
At day 0 HRECs were seeded in 75 cm2 flask. Using inverted microscope at power 10X 
cell morphology and confluency was monitored (Figure 3A and 3B). 
 
 
  
Figure 4B: Cells adherent to the 
culture plate with 100% confluency. 
 
Figure 4A: Cells adherent to the 
culture plate confluent about 50% to 
Figure 4C: Cells after trypsinazation 
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Cell viability is an essential parameter in verifying the health of HRECs culture and to 
assess the toxic effect of treatment during the experiment. This was achieved by using 
Tali™ Image-based Cytometer. The average cell count of all experiments, including the 
replicates, ranged from 2×106 to 4×106 cell/ml with average size 11-13µm. Cell viability 
was assessed by calculating the number of live and dead cells. Results showed that HG 
decreased the HRECs viability significantly compared with the normoglycemic (control) 
group while ApN-treated HRECs had increased the cell viability compared with HG 
cells. HG group had 15.8% lower cell viability compared to the normoglycemic with a 
significant P-value <0.0001, while HG+ApN group had 4% lower cell viability compared 
to the control group with a significant P-value 0.0235. Comparing HG with HG+ApN 
group, there was a significant decrease (12%) in cell viability in HG with P-value 
<0.0001. For dead cells, HG had 440% increase in the number of dead cells compared to 
control with a significant P-value <0.0001, and 244% increase compared with HG+ApN 
group with a significant P-value <0.001 (Figure 4). Furthermore, normoglycemic cells 
treated with adiponectin and HRECs with mannitol as an osmotic control did show any 
significant difference in the count of living and dead cells with two-tailed p values >0.05 
(Figure 4A and 4B). 
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Figure 5: Effect of high glucose and adiponectin on cell viability. Graph A represents the 
percentage of the live cells. Graph B represents the percentage of the dead cells. The cells 
treated with 5.5mM glucose, 30mM high glucose, 30mM glucose and adiponectin 
(30ug/ml), and normoglycemic cells treated with adiponectin (30uM) and mannitol 
(25mM) as an osmotic control.  The data presented as means (SD) of 3-4 independent 
experiments, analyzed by One-way ANOVA with posthoc Tukey-Kramer multiple 
comparisons test between individual groups. Two-tailed p-value is significant at p<0.05. 
* P <0.05 and **** P <0.0001. 
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5.2 Quality of RNA and miRNA extracted from the treated HRECs 
 
The number of cells before the extraction ranged between 1 and 1.5 million cells. 
After extraction, the quality of extracted RNA and miRNA was assessed before 
proceeding with gene expression and RNA sequencing. Such quality assays are critical in 
all subsequent analysis and data interpretation. The extracted RNA concentration, purity, 
and integrity were assessed. All samples had RNA Integrity Number (RIN) between 8.5 
and 10 out of 10 and 206/280 ratio of 1.8-2.1 as shown in Figure 4. Furthermore, the 
concentration of miRNA and percentage in small RNA was evaluated as shown in Figure 
6, indicating good percentage ranging between 20-38%.  
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Figure 6: Total RNA quality results by 2100 Agilent Bioanalyzer. The Agilent report 
includes an electropherogram, RNA integrity number (RIN), and RNA concentration. 
RIN is a scale range between 0 to 10, where 0 represent degraded RNA sample and 10 
represent highly intact RNA. 
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Figure 7: miRNA quality results by 2100 Agilent Bioanalyzer. The Agilent report 
includes an electropherogram, RNA integrity number (RIN), and RNA concentration. 
RIN is a scale range between 0 to 10, where 0 represent degraded RNA sample and 10 
represent highly intact RNA. 
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5.3 Effect of Adiponectin Treatment on Adiponectin Receptors Expression 
 The effect of ApN on HRECs is exerted through its receptors, AdipoR1 and 
AdipoR2. Determining the expression of ApN receptors, using RT-PCR, could help in 
understanding the mechanism of ApN in DR pathogenesis. AdipoR1 was significantly 
decreased in HG group by 0.73 fold compared to NG group with P-value <0.001, while 
the expression of AdipoR1 increased significantly in HG+ApN (1.9 folds) compared to 
hyperglycemic cells with P-value<0.0001.Similarly, AdipoR2 showed the same 
expression pattern where the expression of AdipoR2 increases significantly in HG+ApN 
compared to hyperglycemic cells with P-value<0.001. Furthermore, HG downregulated 
the expression of AdipoR1 and AdipoR2 in HRECs by 0.73 and 0.65 fold change 
respectively. Using the qPCR, the expression of the two receptors were upregulated in 
HG-treated with adiponectin and, AdipoR1 mRNA expression increased by 1.86 fold 
changes than AdipoR2mRNA expression in ApN treated HG cells with P-value<0.0001 
(Figure 7). 
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Figure 8: Gene expression analysis by RT-PCR for adiponectin receptor 1 (AdipoR1) 
and adiponectin receptor 2 (AdipoR2) mRNA in HREC. HG group treated with high 
glucose concentration (30mM) for 24 hours and HG+ApN with both high glucose 
concentration (30mM) and ApN (30µg/mL). Bars show the data presented as means with 
a standard deviation of three independent experiments analyzed by one-way ANOVA and 
posthoc multiple comparison tests. Two-tailed P-value is significant at p≤0.05.  For 
AdipoR1, *** HG is significantly different from the control group, and after ApN 
treatment (P≤0.001). For AdipoR2, ** both HG and HG+ApN groups are significantly 
different from the control group (P<0.01).   
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5.4 Effect of Adiponectin on Inflammation and VEGF-A mRNA Expression 
The expression of inflammatory biomarker IL-6 in HRECs cells under high 
glucose as well as adiponectin treatment conditions was examined. The level of IL-6 was 
significantly increased in HG group compared to NG with P-value <0.001 and decreased 
significantly in HG group treated with ApN compared to HG group by 1.5 folds with P-
value 0.0135 (Figure 8). Also, there was a significant increase in IL-6 level in HG+ApN 
compared with NG (P-value 0.0018).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: IL-6 cytokine in the supernatant of HRECs (conditioned media) after different 
treatments using multiplex ELISA. The data presented as means (SD) of 3-4 independent 
experiments, analyzed by One-way ANOVA with posthoc Tukey-Kramer multiple 
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comparisons test between individual groups. Two-tailed p-value is significant at p<0.05. 
* P <0.05, ** P <0.01and *** P <0.001. 
 
 
The expression of VEGFA mRNA after high glucose treatment significantly 
increased compared to NG with (P-value 0.0025) (Figure 9). However, the VEGF-A 
expression significantly reduced after ApN treatment to HG cells (P-value <0.0001). 
Similarly, the expression was significantly decreased in HG+ApN group compared to NG 
(P-value 0.0031). Although ApN decreased the expression of VEGF-A in high glucose-
treated cell, it increased the expression of VEGF-A in ApN-treated HRECs. However, 
these finding are at gene expression level and need to be examined at protein level. 
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Figure 10: Gene expression analysis by RT-PCR for VEGF-A mRNA in HREC. The 
data presented as means (SD) of 3-4 independent experiments, analyzed by One-way 
ANOVA with posthoc Tukey-Kramer multiple comparisons test between individual 
groups. Two-tailed p-value is significant at p<0.05. ** P <0.01, *** P <0.001 and **** P 
<0.0001. 
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5.5 Analysis of miRNA Expression 
5.5.1 RT-PCR Profiler 
RT-PCR profiler plates were used to screen for adhesion and angiogenesis genes 
commercially provided by the company. The array consists of 84 genes of 
adhesion/angiogenesis. Using the 2 as fold regulation cut off the results of HG+ApN 
group was compared with HG. There was downregulation of most of the adhesion as well 
as angiogenesis genes (Figure 10 and Table 9). For each panel of the identified DEG, a 
list of miRNAs regulating the up and downregulated genes was predicted (Table 10).   
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A. HG group compared to HG+ApN after 24 hours treatment (Adhesion molecules gene 
panel) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: The scatterplot compares the normalized expression of each gene on the array 
between the two selected groups by plotting them against one another to visualize 
substantial gene expression changes. The central line indicates unchanged gene 
expression. The dotted lines indicate the chosen fold regulation threshold. Data points 
beyond the dotted lines in the upper left and lower right sections meet the selected fold 
regulation threshold. 
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Table 9: The list of the adhesion genes over and under-expressed in HG+ApN group vs. 
HG group 
 
Gene Gene ID  Fold Change 
VCAM1 P19320 29.76 
SELL P14151 -20.57 
ITGAL P20701 18.60 
COL8A1 P27658 -13.55 
COL12A1 Q99715 -12.43 
ECM1 Q16610 -10.16 
ADAMTS8 Q9UP79 10.08 
MMP14 P50281 -9.67 
ITGB2 P05107 -9.10 
THBS3 P49746 -9.04 
CTNNB1 P35222 -8.33 
COL16A1 Q07092 -8.27 
MMP8 P22894 7.66 
COL6A2 P12110 -7.28 
CD44 P16070 -7.23 
ITGA1 P56199 -7.00 
COL1A1 P02452 6.63 
TIMP1 P01033 -6.53 
ITGB4 P16144 -6.42 
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Data represent the changes in gene expression by fold changes. The red color indicates 
upregulation, and the black with minus value indicates downregulation. The gene symbol 
name symbol and its gene ID are provided. 
 
 
 
 
Figure 12: Adhesion genes over and under-expressed in HG+ApN group vs. HG group 
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Table 10: The list of miRNAs regulating adhesion genes under and over-expressed in 
HG+ApN vs. HG group 
 
Under- Expressed Genes Over- Expressed Genes 
miRNA Name Target Genes miRNA Name Target Genes 
hsa-miR-1304-5p ITGA1 hsa-miR-590-3p VCAM1 
hsa-miR-330-3p CTNNB1 hsa-miR-23a-3p ITGAL 
hsa-miR-9-5p ITGB4 hsa-miR-23b-3p ITGAL 
hsa-miR-519b-3p ITGB4 hsa-miR-1178-3p VCAM1 
hsa-miR-519c-3p ITGB4 hsa-miR-519b-3p ADAMTS8 
hsa-miR-519a-3p ITGB4 hsa-miR-519a-3p ADAMTS8 
hsa-miR-449b-5p COL12A1 hsa-miR-519c-3p ADAMTS8 
hsa-miR-449a COL12A1 hsa-miR-203a ADAMTS8 
hsa-miR-34c-5p COL12A1 hsa-miR-218-5p COL1A1 
hsa-miR-101-3p COL12A1 hsa-miR-944 COL1A1 
hsa-miR-423-5p THBS3 hsa-miR-193a-5p COL1A1 
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hsa-miR-587 COL12A1 hsa-miR-577 COL1A1 
hsa-miR-34a-5p COL12A1 hsa-miR-143-3p COL1A1 
hsa-miR-526b-5p CTNNB1 hsa-miR-516a-3p COL1A1 
hsa-miR-374a-5p MMP14 hsa-miR-371a-5p COL1A1 
hsa-miR-431-5p COL12A1 hsa-miR-548d-3p COL1A1 
hsa-miR-298 COL12A1 hsa-miR-153-3p ADAMTS8 
hsa-miR-214-3p CTNNB1 hsa-let-7g-5p ADAMTS8, COL1A1 
hsa-miR-374b-5p MMP14 hsa-let-7i-5p ADAMTS8, COL1A1 
hsa-miR-1244 COL12A1 hsa-let-7d-5p ADAMTS8, COL1A1 
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B. HG group compared to HG+ApN after 24 hours treatment (Angiogenesis panel) 
 
 
 
Figure 13: The scatterplot compares the normalized expression of every gene on the 
array between the two selected groups by plotting them against one another to visualize 
substantial gene expression changes. The central line indicates unchanged gene 
expression. The dotted lines indicate the selected fold regulation threshold. Data points 
beyond the dotted lines in the upper left and lower right sections meet the selected fold 
regulation threshold.  
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Table 11: Angiogenesis genes over and under-expressed in HG+ApN vs. HG group 
 
Gene 
Symbol 
Gene ID Fold 
Regulation 
Gene 
Symbol 
Gene ID Fold 
Regulation 
ADAM17 P78536 -2.66 MMP9 P14780 -2.26 
AGT B0ZBE2 -2.26 NPPB P16860 -2.26 
AGTR1 P30556 -2.26 NPR1 P16066 -3.58 
ALOX5 P09917 -2.26 OCLN Q16625 -11.37 
ANGPT1 Q15389 -5.93 PF4 P02776 -2.26 
APOE P02649 -5.96 PLG P00747 -2.26 
BCL2 P10415 -2.72 PTGIS Q16647 -2.26 
BCL2L1 Q07817 2.65 PTGS2 P35354 2.96 
CALCA P06881 -3.20 SELE P16581 14.79 
CCL2 P13500 248.06 SELL P14151 -2.50 
CCL5 P13501 -2.26 SELPLG Q14242 5.99 
CX3CL1 P78423 -5.08 THBD P07204 2.36 
EDN2 P20800 -2.26 TNF P01375 -2.26 
EDNRA P25101 -6.05 VCAM1 P19320 5.97 
FGF1 P05230 -2.26 KLK3 P07288 -3.53 
ICAM1 P05362 4.20 IL1B P01584 -2.26 
IL11 P20809 -2.26 IL3 P08700 -8.96 
F3 P13726 -2.26 FASLG P48023 -2.26 
FAS P25445 -3.31 IL7 P13232 -2.26 
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Figure 14: Angiogenesis genes over and under-expressed in HG+ApN group vs. HG 
group. 
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Table 12: miRNA regulating angiogenesis genes under and over-expressed in HG+ApN 
vs. HG group. 
 
Under- Expressed Genes Over- Expressed Genes 
miRNA Name Target Genes miRNA Name Target Genes 
hsa-miR-23a-3p FAS hsa-miR-374b-5p CCL2 
hsa-miR-23b-3p FAS hsa-miR-374a-5p CCL2 
hsa-miR-889-3p OCLN hsa-miR-26b-5p PTGS2 
hsa-miR-149-5p EDNRA hsa-miR-1297 PTGS2 
hsa-miR-153-3p ANGPT1 hsa-miR-26a-5p PTGS2 
hsa-miR-122-5p OCLN hsa-miR-590-3p VCAM1 
hsa-miR-767-3p NPR1 hsa-miR-381-3p SELE 
hsa-miR-448 BCL2 hsa-miR-513b-5p PTGS2 
hsa-miR-145-5p ADAM17 hsa-miR-300 SELE 
hsa-miR-224-5p ADAM17 hsa-miR-1305 SELE 
hsa-miR-568 BCL2 hsa-miR-377-3p SELE 
hsa-miR-204-5p ANGPT1, BCL2 hsa-miR-1178-3p VCAM1 
hsa-miR-211-5p ANGPT1, BCL2 hsa-miR-767-5p SELE 
hsa-miR-520g-3p ANGPT1 hsa-miR-101-3p PTGS2 
hsa-miR-98-5p FAS hsa-miR-1286 ICAM1 
hsa-let-7g-5p FAS hsa-miR-576-3p PTGS2 
hsa-let-7f-5p FAS hsa-miR-144-3p PTGS2 
hsa-let-7c-5p FAS hsa-miR-1827 PTGS2 
hsa-let-7i-5p FAS hsa-miR-143-3p PTGS2 
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C. HG group compared to NG after 96 hours treatment (Angiogenesis panel) 
Comparing HG group treated for 96 hours with high glucose to NG group, there 
was an up-regulation of many angiogenesis genes as shown the scatter plot below.  A 
significant increase was shown in adhesion G protein-coupled receptor B1 (ADGRB1) 
gene as it reached 470 fold change as indicated in the heat map (Figure 15). After ApN 
treatment, there was a decrease in the fold change of up-regulated genes in HG group but 
still not as NG level (Figure 13).  
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Figure 15: The scatterplot compares the normalized expression of each gene on the array 
between the two selected groups by plotting them against one another to quickly visualize 
substantial gene expression changes. The central line indicates unchanged gene 
expression. The dotted lines indicate the selected fold regulation threshold. Data points 
beyond the dotted lines in the upper left and lower right sections meet the selected fold 
regulation threshold. 
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Table 13: List of the angiogenesis genes over and under-expressed in HG group vs. NG 
group after 96 hours treatment 
 
 
 
 
Data shows that most of the angiogenesis genes were upregulated in HG group compared 
to control. This supports that high glucose condition could induce different pathological 
changes including angiogenesis in HRECs. 
   
Gene 
Symbol 
Gene ID Fold 
Regulation 
Gene 
Symbol 
Gene ID Fold 
Regulation 
ANG P01019 3.36 THBS2 P35442 -21.23 
ADGRB1 O14514 470.51 HGF P08581 4.65 
CCL11 P51671 2.12 IGF1 P05019 2.22 
COL4A3 Q01955 2.46 IL1B P01584 -2.14 
CXCL1 P09341 -2.23 PLG P00747 4.21 
CXCL9 Q07325 6.58 IFNG P01579 3.45 
EGF P01133 4.53 PROK2 Q9HC23 -3.10 
FGF1 P05230 14.93    
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Figure 16: Angiogenesis genes over and under-expressed in HG group vs. NG group 
after 96 hours of treatment. Of note, ADGRB1 gene had 470.51 fold change and could 
not be plotted on this graph as it will shift all other genes expression down and make the 
graph challenging to visualize. 
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Figure 17: The Heat Map provides a visualization of the fold changes in expression 
between the selected groups for every gene in the array in the context of the array layout. 
The table provides the fold regulation data used for the map as well as the comments 
associated with each one.  
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Table 14: miRNA regulating angiogenesis genes under and over-expressed in HG vs. NG 
group 
Under- Expressed Genes Over- Expressed Genes 
miRNA Name Target Genes miRNA Name Target Genes 
hsa-miR-101-3p PROK2 hsa-miR-590-3p IGF1 
hsa-miR-591 THBS2 hsa-miR-425-5p IGF1 
hsa-miR-182-5p THBS2 hsa-miR-875-3p COL4A3 
hsa-miR-885-5p PROK2 hsa-miR-1275 IGF1 
hsa-miR-891b THBS2 hsa-miR-381-3p FGF1 
hsa-miR-23a-3p PROK2 hsa-miR-21-5p FGF1 
hsa-miR-23b-3p PROK2 hsa-miR-590-5p FGF1 
hsa-miR-374a-5p PROK2 hsa-miR-300 FGF1 
hsa-miR-598-3p THBS2 hsa-miR-625-5p IGF1 
hsa-miR-374b-5p PROK2 hsa-miR-148b-3p IGF1 
hsa-miR-922 THBS2 hsa-miR-148a-3p IGF1 
hsa-miR-641 CXCL1 hsa-miR-152-3p IGF1 
hsa-miR-524-5p THBS2 hsa-miR-125a-5p COL4A3 
hsa-miR-520d-5p THBS2 hsa-miR-125b-5p COL4A3 
hsa-miR-30b-5p THBS2 hsa-miR-484 FGF1 
hsa-miR-30a-5p THBS2 hsa-miR-582-5p HGF 
hsa-miR-30d-5p THBS2 hsa-miR-519d-3p COL4A3 
hsa-miR-30e-5p THBS2 hsa-miR-93-5p COL4A3 
hsa-miR-30c-5p THBS2 hsa-miR-20b-5p COL4A3 
hsa-miR-96-5p PROK2, THBS2 hsa-miR-106a-5p COL4A3 
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D. HG+ApN group compared to HG after 96 hours treatment (Angiogenesis panel) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: The scatterplot compares the normalized expression of every gene on the 
array between the two selected groups by plotting them against one another to quickly 
visualize substantial gene expression changes. The central line indicates unchanged gene 
expression. The dotted lines indicate the selected fold regulation threshold. Data points 
beyond the dotted lines in the upper left and lower right sections meet the selected fold 
regulation threshold. 
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Figure 19: Angiogenesis genes over and under-expressed in HG+ApN group vs. HG 
group after 96 hours of treatment. ADGRB1 gene had -173.39 fold change and could not 
be plotted on this graph as it will shift all other genes expression down and make the 
graph challenging to visualize. 
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Figure 20: The Heat map provides a visualization of the fold changes in expression 
between the selected groups for every gene in the array in the context of the array layout. 
The table provides the fold regulation data used for the map as well as the Comments 
associated with each one. 
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E. HG+ApN group compared to NG after 96 hours treatment (Angiogenesis panel) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: The scatterplot compares the normalized expression of every gene on the  
array between the two selected groups by plotting them against one another to quickly 
visualize substantial gene expression changes. The central line indicates unchanged gene 
expression. The dotted lines indicate the selected fold regulation threshold. Data points 
beyond the dotted lines in the upper left and lower right sections meet the selected fold 
regulation threshold. 
 
Lo
g1
0 
(N
or
m
al
iz
ed
 E
xp
re
ss
io
n
 H
G
+A
p
N
 g
ro
u
p
) 
 72 
 
Table 15: Angiogenesis genes under and over-expressed in HG+ApN vs. NG group 
 
 
 
Dara represents the angiogenesis gene expression in HRECs after 96 hours in high 
glucose condition followed by 24 hours ApN treatment and then compared with the 
control. Although many genes were still upregulated even after ApN treatment, the fold 
change was lower compared with HG group. This shows that ApN downregulated 
angiogenesis genes but still not at the control level.  
Gene symbol Gene ID Fold Change Gene symbol Gene ID Fold Change 
THBS2 P35442 -8.17 HGF P14210 2.71 
TGFA P01135 -4.19 IFNG P01579 2.71 
PROK2 Q9HC23 -3.66 IGF1 P05019 2.71 
ANG P03950 5.50 IL1B P01584 8.62 
ADGRB1 O14514 2.71 IL6 P05231 2.18 
CCL2 P13500 3.75 CXCL8 P10145 2.63 
CXCL1 P09341 4.83 MMP9 P14780 2.55 
CXCL10 P02778 2.71 PF4 P02776 3.47 
CXCL5 P42830 3.32 PLG P00747 2.71 
CXCL6 P80162 3.75 FGF2 P09038 -2.11 
CXCL9 Q07325 2.71 THBS2 P35442 -8.17 
FGF1 P05230 3.50 TNF P01375 2.71 
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Figure 22: Angiogenesis genes over and under-expressed in HG+ApN group vs. NG 
group after 96 hours of treatment.  
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Table 16: miRNA regulating angiogenesis genes under and over-expressed in HG+ApN vs. 
NG group 
Under- Expressed Genes Over- Expressed Genes 
miRNA Name Target Genes miRNA Name Target Genes 
hsa-miR-1178-3p TGFA hsa-miR-590-3p IGF1 
hsa-miR-591 THBS2 hsa-miR-374a-5p CCL2 
hsa-miR-148a-3p TGFA hsa-miR-374b-5p CCL2 
hsa-miR-148b-3p TGFA hsa-miR-425-5p IGF1 
hsa-miR-152-3p TGFA hsa-miR-1323 CXCL6 
hsa-miR-101-3p PROK2, TGFA hsa-miR-548o-3p CXCL6 
hsa-miR-182-5p THBS2 hsa-miR-206 IGF1 
hsa-miR-885-5p PROK2 hsa-miR-1 IGF1 
hsa-miR-891b THBS2 hsa-miR-613 IGF1 
hsa-miR-205-5p TGFA hsa-miR-1275 IGF1 
hsa-miR-942-5p TGFA hsa-miR-21-5p FGF1 
hsa-miR-23b-3p PROK2, TGFA hsa-miR-381-3p FGF1 
hsa-miR-374a-5p PROK2, TGFA hsa-miR-590-5p FGF1 
hsa-miR-23a-3p PROK2, TGFA hsa-miR-300 FGF1 
hsa-miR-598-3p THBS2 hsa-miR-625-5p IGF1 
hsa-miR-374b-5p PROK2, TGFA hsa-miR-148b-3p IGF1 
hsa-miR-922 THBS2 hsa-miR-148a-3p IGF1 
hsa-miR-301b TGFA hsa-miR-152-3p IGF1 
hsa-miR-301a-3p TGFA hsa-miR-484 FGF1 
hsa-miR-140-3p TGFA hsa-miR-582-5p HGF 
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5.5.2 RNA Sequencing 
Before analyzing the sequencing results, the quality of run should be evaluated. 
Using FastQC software, the average of Q score across all bases was 36 which indicate 
approximately 99.99% accuracy of base calling (Figure 23 and 24). After checking the 
quality of sequencing, trimming of the reads was done to remove adapter sequences, any 
ambiguous nucleotides and restricting the fragment size to miRNA size (Figure 25). 
Principal Component Analysis (PCA) is a method for compressing a broad set of data 
into a smaller set that captures the essence of the original data. The graph usually shows 
the clustering of cells’ transcriptions with a similar profile. In our study, most of the 
groups with the same transcription profile clustered together (Figure 26) except for one 
control group that was an outlier and showed different transcription. This could be due to 
biological variability between samples. Therefore, for all comparisons involving control 
groups, the sample NC1 was excluded because it clustered with HG samples on the PCA 
plot (Figure 26). For comparisons that involved replicates, differentially expressed 
miRNAs were found using DEseq2 (R package). Comparison of differentially expressed 
miRNAs from different groups of treated HRECs revealed 14 miRNAs, of which 12 were 
up-regulated and two down-regulated (Table 17 and Figure 27). 
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Figure 23: Quality scores (Phred score) across all bases. All bases had a score of 30 and 
above which indicate 99.9% accuracy of base calling during the sequencing. 
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Figure 24: Quality scores (Phred score) distribution over all sequences. The average 
score is 36 which indicate 99.99% accuracy of base calling during the sequencing. 
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Figure 25: Reads length before and after trimming 
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Figure 26: Principal Component Analysis of all samples. It is a statistical procedure used 
to visualize the distribution of the samples and whether is an outlier. 
  
Outlier 
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Table 17: Significantly differentially expressed miRNAs (P-value < 0.05; regulated 
greater than 2-fold change or less than -2) due to hyperglycemia (96 hours, 30mM 
glucose) compared to normoglycemia (NG).  
 
 
 
 
miRNA P-value Fold change Style 
hsa-let-7a-5p 8.47E-08 2.30 Up 
hsa-let-7c-5p 9.91E-05 1.64 Up 
hsa-let-7e-5p 5.78E-05 1.60 Up 
hsa-let-7f-5p 2.72E-07 2.34 Up 
hsa-let-7g-5p 1.45E-05 1.74 Up 
hsa-miR-224-5p 8.00E-06 1.79 Up 
hsa-miR-26b-5p 2.37E-05 1.66 Up 
hsa-miR-30c-5p 5.56E-05 1.67 Up 
hsa-miR-493-5p 2.43E-05 2.13 Up 
hsa-miR-543 3.17E-05 2.18 Up 
hsa-miR-887-3p 0.000132989 -1.91 Down 
hsa-miR-98-5p 3.72E-06 2.14 Up 
has-miR-27a 5.82E-03 -5.00 Down 
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Table 18: Significantly differentially expressed miRNAs (P-value < 0.05; regulated 
greater than 2-fold change or less than -2) due to high glucose (96 hours, 30mM glucose) 
compared to ApN treatment (24 hours, 30µg/ml). 
 
 
 
Data are presented as fold changes, with P-values (P-value < 0.05; regulated greater than 
2-fold change or less than -2) for miRNA. A total of 13 miRNAs were dysregulated in 
HG group compared to the control while one miRNA, miR-146a-5p, was solely detected 
in ApN treated HRECs. 
  
miRNA P-value Fold change Style 
hsa-miR-146a-5p 3.88E-05 1.16 
Up (solely detected 
in ApN treated cells) 
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Figure 27: Significantly differentially expressed miRNAs (P-value < 0.05; regulated 
greater than 2-fold change or less than -2) due to hyperglycemia and ApN treatment (24 
hours, 30µg/mL).  
 
  
h
s
a
- l
e
t -
7
a
-5
p
h
s
a
- l
e
t -
7
c
-5
p
h
s
a
- l
e
t -
7
e
-5
p
h
s
a
- l
e
t -
7
f -
5
p
h
s
a
- l
e
t -
7
g
-5
p
h
s
a
-m
iR
-2
2
4
-5
p
h
s
a
-m
iR
-2
6
b
-5
p
h
s
a
-m
iR
-3
0
c
-5
p
h
s
a
-m
iR
-4
9
3
-5
p
h
s
a
-m
iR
-5
4
3
h
s
a
-m
iR
-8
8
7
-3
p
h
s
a
-m
iR
-9
8
-5
p
h
s
a
-m
iR
-2
7
a
h
s
a
-m
iR
-1
4
6
a
-5
p
-6
-4
-2
0
2
4
m iR N A s
F
o
ld
 C
h
a
n
g
e
 83 
 
After normalization of raw sequencing data, analyzing them and performing 
differential gene expression comparison of miRNAs from different treated groups, related 
pathways of the dysregulated miRNAs were determined. This was achieved by searching 
various databases, such as miRsystem and Target-scan, and the target genes are 
summarized in Table 18. 
 
 
Table 19: Summary of the miRNAs’ targeted pathways and genes in HG vs.NG. 
 
miRNAs Targeted Pathway Target Genes EnterzID 
hsa-miR-27a Cytokine receptor interaction EGFR 1956 
  LIFR 3977 
 Chemokine signaling pathway GNB5 10681 
 Insulin signaling pathway FOXO1 2308 
  MKNK2 2872 
  RPTOR 57521 
  MYO1C 4641 
 Gluconeogenesis ALDH9A1 223 
 Pyruvate metabolism ALDH9A1 223 
 Metabolic pathways ALDH9A1 223 
  PFAS 5198 
  GPAM 57678 
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 Angiogenesis APC 324 
 Cadherin signaling pathway EGFR 1956 
 Interleukin signaling pathway MKNK2 2872 
 Oxidative stress response DUSP5 1847 
  MKNK2 2872 
  NFE2L2 4780 
  SP1 6667 
 Matrix Metalloproteinases MMP13 4322 
 TNF alpha Signaling Pathway FADD 8772 
  CUL1 8454 
hsa-let-7a-5p Gluconeogenesis ALDH7A1 501 
 Metabolic pathways ADSL 158 
 AMPD2 271 
 AOC2 314 
 DAD1 1603 
 LTA4H 4048 
  MTHFD1 4522 
 Cytokine receptor interaction BMPR1B 658 
EGFR 1956 
IL6 3569 
Chemokine signaling pathway HRAS 3265 
NFKB1 4790 
VEGF signaling pathway HRAS 3265 
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KRAS 3845 
NRAS 4893 
Cell adhesion molecules CAMs CD276 80381 
Adipocytokine signaling 
pathway 
NFKB1 4790 
Type II diabetes mellitus PIK3R1 5295 
hsa-let-7c-5p Gluconeogenesis LDHA 3939 
 Metabolic pathways CHST6 4166 
 NME4 4833 
 PTGS1 5742 
 Cytokine receptor interaction ACVR1B 91 
 MPL 4352 
 Chemokine signaling pathway FOXO3 2309 
 GSK3A 2931 
 NRAS 4893 
 VEGF signaling pathway PTGS2 5743 
 PTK2 5747 
hsa-let-7e-5p Metabolic pathways AMPD2 271 
  POLR3D 661 
  COX10 1352 
  FDPS 2224 
  GLUL 2752 
 Cytokine receptor interaction TNFRSF1A 7132 
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 Chemokine signaling pathway CRK 1398 
 PTK2 5747 
 RAP1A 5906 
 VEGF signaling pathway PTK2 5747 
 Type I diabetes mellitus HLA-C 3107 
 Type II diabetes mellitus IRS4 8471 
 IRS2 8660 
 Cell adhesion molecules CAMs CLDN4 1364 
  HLA-C 3107 
hsa-let-7f-5p Gluconeogenesis ALDH7A1 501 
Metabolic pathways ATP5B 506 
CYP19A1 1588 
FDPS 2224 
GLUL 2752 
Cytokine receptor interaction EDA 1896 
IL13 3596 
 
hsa-let-7g-5p Metabolic pathways RRM2 6241 
RPL12 6136 
Cytokine receptor interaction IL13 3596 
Chemokine signaling pathway KRAS 3845 
VEGF signaling pathway KRAS 3845 
hsamiR-224-5p Metabolic pathways ARSB 411 
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 Cytokine receptor interaction CD40 958 
 PDGFRB 5159 
 CXCR4 7852 
 Chemokine signaling pathway CDC42 998 
 CXCR4 7852 
 VEGF signaling pathway CDC42 998 
 Cell adhesion molecules CAMs CD40 958 
hsa-miR-26-5p Gluconeogenesis PDHA2 5161 
PFKP 5214 
Metabolic pathways NAT1 9 
ACADM 34 
AGL 178 
AK4 205 
Cytokine receptor interaction CXCL9 4283 
IL12A 3592 
Chemokine signaling pathway ARRB1 408 
FOXO3 2309 
NFKB1 4790 
VEGF signaling pathway PPP3R1 5534 
PTGS2 5743 
Cell adhesion molecules CAMs CDH1 999 
CDH5 1003 
Type II diabetes mellitus INSR 3643 
PIK3CG 5294 
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Type I diabetes mellitus FASLG 356 
CD28 940 
IL12A 3592 
hsa-miR-30c-5p Gluconeogenesis PKM 5315 
Metabolic pathways DDOST 1650 
HPRT1 3251 
MGAT2 4247 
Cytokine receptor interaction CSF1 1435 
Chemokine signaling pathway PIK3R2 5296 
MAP2K1 5604 
VEGF signaling pathway RAC1 5879 
RAC3 5881 
Cell adhesion molecules CAMs CDH1 999 
ITGA4 3676 
Type II diabetes mellitus ITGA4 3676 
PIK3R2 5296 
PKM 5315 
SOCS1 8651 
hsa-miR-887-3p Metabolic pathways MTHFD1L 25902 
hsa-miR-98-5p Metabolic pathways MCAT 27349 
Cytokine receptor interaction FAS 355 
CXCL2 2920 
IL6 3569 
Chemokine signaling pathway CCL5 6352 
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 CXCL2 2920 
VEGF signaling pathway NRAS 4893 
Type II diabetes mellitus HK2 3099 
IRS2 8660 
Type I diabetes mellitus FAS 355 
hsa-miR-146a-5p Cytokine receptor interaction FAS 355 
 CXCR4 7852 
IL8 3576 
Chemokine signaling pathway CCR9 10803 
NFKB1 4790 
CXCR4 7852 
Cell adhesion molecules CAMs ITGB2 3689 
L1CAM 3897 
 Adipocytokine signaling 
pathway 
NFKB1 4790 
 Type I diabetes mellitus FAS 355 
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 6. DISCUSSION 
 
Diabetic retinopathy (DR) is one of the chronic complications of diabetes that 
causes breakdown of retinal vasculature due to persistent hyperglycemia. It is considered 
the leading cause of vision loss and blindness among people worldwide (1). DR is ranked 
as the fifth most common cause of moderate to severe visual impairment and 
characterized by endothelial cell dysfunction, the breakdown of the BRB, and retinal 
neovascularization. Therefore, practical therapeutic approaches are required to control the 
progression of DR. Understanding the molecular mechanisms including the expression of 
the genes and their regulatory molecules such as miRNA and biological pathways in 
diabetic conditions, could help to reveal the pathogenesis of this complicated process.  
miRNAs are small non-coding RNA molecules that negatively regulate the gene 
expression and therefore play a crucial role in disease processes. They have been 
documented as novel biomarkers, and numerous studies showed the relationship between 
miRNA and the regulation of different pathways including angiogenesis (144). 
Furthermore, ApN is a hormone produced in human adipose tissue, and the data 
demonstrated that ApN could ameliorate critical biological process involved in the 
pathogenesis of DR in HRECs (135). It acts as an anti-inflammatory, insulin-sensitizing 
and suppresses the formation of neovascularization (145). Recent studies showed that 
ApN regulates the expression of different inflammatory as well as angiogenesis and 
adhesion genes including IL-6, VEGF-A, ICAM-1, and integrity of the BRB in the 
diabetic retina. However, ApN therapeutic mechanism is not well-understood. One of the 
regulators that could have a role in the ApN action is miRNA. Based on this we aimed to 
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investigate the effect of hyperglycemia on miRNA in vitro using HRECs and the impact 
of ApN on miRNA expression and related molecular pathways in HRECs exposed to the 
hyperglycemic conditions. The current study establishes some significant findings that 
help in describing the role of hyperglycemia and ApN in expressing different miRNAs in 
HRECs. These findings are discussed in the following paragraphs. 
In the current study, the exposure of HRECs to high glucose (30mM)  causes a 
significant reduction in the cell viability,  whereas administration of ApN to 
hyperglycemic HRECs counteract such effect and maintains the cell viability and 
promotes a significant decrease in cell death. Several studies supported this finding and 
are consistent with our results. For instance, a study conducted on HRECs cultured with 
increasing glucose concentrations for different time intervals showed a decrease in cell 
viability. A concentration of 30mM of glucose reduced the viability of HREC in a dose-
dependent manner (146). This phenomenon was observed in other cell types as well as in 
animal models. A study conducted on retinal endothelial cells of Rhesus monkey showed 
that cell viability significantly differed after 24 hours of different glucose treatments. 
Cells treated with normal glucose concentration, 5.5mM, had an increase in cell viability 
in contrast to cells treated with 30mM of glucose which had 20% decrease in cell 
viability (147). In addition, a study conducted on rat retinal capillary endothelial cells 
proved that cells treated with 30mM of glucose for 48 and 72 hours showed a significant 
decrease in cell viability compared to retinal cells treated with 5.5mM glucose (148). 
 Cells treated with ApN showed enhanced cell viability compared to cells treated 
with high glucose. For instance, a recent study on NRK-52E cell line indicated that 
exposure to high glucose results in a significant decrease in cell viability. This can be 
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partially prevented by ApN since it decreases the cells apoptosis by activating activated 
protein kinase (AMPK) enzyme (149). Similarly, a study examined the effect of ApN on 
porcine aortic endothelial cells cultured in standard and high glucose conditions. Results 
showed that ApN increased the cell viability in both normoglycemic and hyperglycemic 
conditions (150). This, in turn, could improve the retinal cell function and BRB in DR 
(135). 
APN performs various biologic actions through its receptors. The data of the 
current study demonstrated that Both ApN receptors, AdipoR1 and AdipoR2 mRNA 
expression were significantly downregulated in HRECs cultured in high glucose 
condition. Receptors expression significantly increased in ApN-treated HRECs. 
However, the expression was significantly upregulated after treating cells with ApN. 
Moreover, ApNR1 expression was higher compared to ApNR2. These results are 
inconsistent with other findings where the level mRNA of ApNR1 and ApNR2 was 
evaluated (151). The study by Hsu et al. on Retinal cells of STZ-induced diabetic rats 
showed that the levels of ApNR1 and ApNR2 mRNA were significantly higher compared 
to control group (151). Another study performed on type 1 diabetes human retina and 
mouse model concluded that the expression of ApNR1 in the retina was significantly 
elevated compared to control, while ApNR2 expression remained unchanged (152). 
Therefore, ApNR1 may have a significant role in the pathological process of diabetic 
retina while ApNR2 has a minor role (153). Such difference could be justified due to the 
species specificity and the type of animal model used to induce diabetes which is 
different than human retinal cells. Such reduction in expression of the adiponectin 
receptors in response to HG observed in our study, may contribute to decreased 
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adiponectin effect in HRECs. Since the expression of ApN receptors increases after ApN 
treatment, it can exert its therapeutic effect in HRECs via its receptors which can enhance 
the endothelial dysfunction. 
The expression of VEGF-A and IL-6 increased in HRECs under high glucose 
condition and remarkably decreased in ApN-treated cells. VEGF-A and IL-6 share some 
common characteristics since both are induced by hyperglycemia and hypoxia as well as 
playing a significant role in vascular permeability, inflammation, and angiogenesis (154). 
In the current study hyperglycemia significantly increased the expression of VEGF-A 
compared to normoglycemic conditions in HRECs and reached approximately 2 fold 
change. This increase was counteracted by ApN where the VEGF-A expression 
significantly decreased in ApN-treated cells (P-value <0.0001). Several studies have 
documented a substantial rise in vitreous VEGF levels in PDR (155-158). However, ApN 
could decrease the expression of VEGF. For instance, a study conducted on human 
retinal pigment epithelial cell lines (ARPE-19) revealed that cells treated with ApN had 
lower VEGF mRNA expression. In addition, there was a negative correlation between 
ARPE exposed to ApN and level of VEGF. Therefore, demonstrating the protective 
effect of ApN in diseases associated with angiogenesis (159).  
Interestingly, cells treated with only ApN showed a high expression of VEGF-A. 
In different tissues, ApN could act as an angiogenic factor to form new blood vessels. For 
instance, a study examined the level of ApN and VEGF-A in human chondrosarcoma 
tissues showed a strong correlation between the high level of adiponectin expression and 
VEGF-A expression. ApN induces the expression of VEGF-A in human chondrosarcoma 
cells and consequently promotes angiogenesis (160). However, the case is different in 
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retinal endothelial cells. The increased expression of VEGF-A occurs at the gene level 
but not at the protein level. Although the expression level of VEGF-A mRNA is elevated, 
by ApN administration, still such phenomenon is not well understood yet, and there is a 
suppression at protein level of VEGF-A in HRECs. This was proven by a study stating 
that ApN significantly increased the production of different proteins, including VEGF, in 
osteoblasts but was not the same case in endothelial cells (161).  
Since hyperglycemia induces inflammation, it was expected that IL-6, a pro-
inflammatory cytokine, to be elevated in HG group compared to control. Numerous 
studies showed a significant increase in IL-6 level in diabetic patients (162-164). Since 
ApN acts as an anti-inflammatory molecule, cells treated with ApN showed a 
significantly lower level of IL-6 compared to cells under hyperglycemic conditions. 
Studies showed that patients who have metabolic syndrome with a high level of IL-6, 
TNF-α, and hsCRP concentrations had lower ApN concentrations compared with control 
(165). Moreover, ApN anti-inflammatory actions are exerted by suppressing the binding 
of NF-kB to the DNA, and therefore the level of NF-kB target genes, including IL-6, will 
be suppressed (166). This indicates the therapeutic effect of ApN in improving the retinal 
cell function in DR. By suppressing NF-kB signaling leukocyte adhesion in HRECs will 
be suppressed, hence, decreasing the inflammation and endothelial dysfunction in 
HRECS, especially after the addition of ApN to HG cells. 
Hyperglycemia and ApN treatment affect the expression of multiple adhesion and 
angiogenesis genes in HRECs. The RT-PCR profiler plate consisted of 84 different genes 
that were commercially provided. Comparing the adhesion gene panel of HG and 
HG+ApN groups, revealed that five genes were upregulated in HG+ApN group 
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compared to HG and 15 adhesion genes were downregulated. When examining HRECs 
treated for 24 hours for angiogenesis gene panel, the results showed that seven genes 
were upregulated, and 34 genes were downregulated in HG cells treated with adiponectin 
(HG+ApN) compared to the cells exposed to high glucose (HG). However, when HRECs 
were exposed for high glucose for a longer duration for 96 hours, and then we examined 
them using the same angiogenesis panel, the data revealed that nine genes were 
upregulated and nine genes were downregulated in HG+ApN compared to HG. One of 
the distinctive results in the angiogenesis panel is the expression of adhesion G protein-
coupled receptor B1 (ADGRB1) which had a 470-fold increase in HG compared to 
control. After exposing HRECs to ApN treatment, the fold changed of ADGRB1 mRNA 
expression decreased significantly to -173.39. Searching databases, ADGRB1 is a brain-
specific angiogenesis inhibitor 1 (167). However, no studies have been done on human 
retinal endothelial cells so far, and further studies are needed to explore its role in DR 
genesis. The results of the adhesion gene panel showed that the four most upregulated 
mRNA were of the following genes; VCAM1, ITGAL, ADAMTS8, and MMP8, while 
most downregulated mRNA are for the following four genes SELL, COL8A1, 
COL12A1, and ECM-1.  
The results of the angiogenesis panel in HG cells exposed for short time (24 
hours) and longer time (96 hours) was inconsistent and showed some variations. For 24 
hours exposure to HG followed by adiponectin treatment, the four most upregulated 
genes were SELE, SELPLG, VCAM-1, and ICAM-1 and the four most downregulated 
genes were OCLN, IL-3, APOE, and ANGPT1. For the prolonged time of HG exposure 
(96 hours) followed by ApN treatment demonstrated that the four most upregulated genes 
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were IL-1B CXCL1, CXCL6, and CCL2 while the four most downregulated genes were 
EGF, FGF-1, TGFA, and CXCL9. These genes have chemokine and growth factor 
activities. Table 18 shows the aforementioned genes and the coded proteins. This proves 
that ApN could have a role in suppressing the expression of many adhesion molecule 
genes and therefore reduces the leukostasis and inflammation in retinal cells. 
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Table 20: Most up and downregulated adhesion and angiogenesis genes in HRECs treated cells for 24 and 96 hours (RT-PCR profiler 
results) 
 
24-hour HG exposure and 
treatment 
96-hour HG exposure and 
treatment 
24-hour HG exposure and 
treatment 
96-hour HG exposure and 
treatment 
Upregulated 
genes 
Protein 
code 
Upregulated 
genes 
Protein 
code 
Downregulated 
genes 
Protein code Downregulated 
genes 
Protein code 
        
VCAM-1 Vascular cell 
adhesion 
protein 1 
IL-1B Interleukin-1 
Beta 
SELL L-selectin EGF Pro-epidermal 
growth factor 
ITGAL Integrin alpha-
L 
CXCL1 Growth-
regulated alpha 
protein 
COL8A1 Collagen 
alpha-1(VIII) 
chain 
FGF-1 Fibroblast 
growth factor 
1 
ADAMTS8 A disintegrin CXCL6 C-X-C motif COL12A1 Collagen TGFA Protransformi
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and 
metalloprotein
ase with 
thrombospondi
n motifs 8 
chemokine 6 alpha-1(XII) 
chain 
ng growth 
factor alpha 
MMP8 Neutrophil 
collagenase 
CCL2 C-C motif 
chemokine 2 
ECM-1 Extracellular 
matrix protein 
1 
CXCL9 C-X-C motif 
chemokine 9 
SELE E-selectin PF4 Platelet factor 4 OCLN Occludin ADGRB1 Brain-specific 
angiogenesis 
inhibitor 1 
SELPLG P-selectin 
glycoprotein 
ligand 1 
CXCL8 Interleukin 8 IL-3 Interleukin-3 GAPDH Glyceraldehy
de-3-
phosphate 
dehydrogenas
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e 
ICAM-1 Intercellular 
adhesion 
molecule 1 
IFNA1 Interferon, 
alpha 1 
APOE Apolipoprotein 
E 
 COL4A3 Collagen, 
type IV, alpha 
3 
(Goodpasture 
antigen) 
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miRNAs are commonly dysregulated in pathological conditions including DR. 
Here we present the miRNAs expressed under high glucose state and after ApN treatment 
in HRECs using the small RNA sequence technique. In the current study, a total of 14 
miRNAs were differentially expressed (P<0.05) in HRECs under different conditions. 
Other studies showed higher numbers of differentially expressed miRNAs; however, 
those studies were conducted on diabetic rats rather than human cells using both RNA 
sequence and microarray (152, 168). Another reason could be that the number of detected 
miRNA in retinal endothelial cells is considerably lower than miRNAs in total retina 
differences in cellular composition complexity (152). 
Comparing the current results of RT-PCR profiler with the present results of RNA 
sequencing analysis with bioinformatics, demonstrated that there were no common 
miRNAs identified between the two approaches. This shows the limitation of RT-PCR 
profiler plates pre-coated with specific known genes since it restricts the screening to 
particular genes and prevents the discovery of new miRNAs beyond the customized 
assay. For instance, a study was performed to evaluate different bioinformatics methods 
to study miRNAs (169). It was suggested that there are some challenges in this field 
since, for example, conventional microarray probes could miss miRNAs of the same 
family and varies by few nucleotides. Another challenge is the cross-hybridization 
between similar miRNAs sequences which could affect the outcome. Therefore, in the 
current study, we used different approaches to screen, compare, and validate the miRNA 
results. 
Different databases were used to search for the gene targets of differentially 
expressed miRNAs, obtained by small-RNA-Seq. Results showed that most of them were 
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involved in various common pathways including cytokine-cytokine receptor interaction, 
chemokine signaling pathway, VEGF signaling pathway, cell adhesion molecules, and 
diabetes mellitus. Others had distinctive involvement in other pathways (table 18). For 
instance, gene ontology results for miR-27 showed that it is involved in angiogenesis, 
cadherin signaling pathway, oxidative stress response as well as gluconeogenesis. This 
was supported by various studies since miR-27a expression was upregulated by high 
glucose and targeted the PPARγ gene in streptozotocin-induced diabetic rats (170). 
Moreover, a study concluded that miR-27a might have an association with type 1 and 2 
diabetes (171, 172). Similarly, a recent study showed that glucose intolerance in mice 
resulted from miR-let-7 overexpression despite the increase in insulin secretion (173). 
Out of the 14 differentially expressed miRNAs, 13 were expressed in HRECs 
exposed to hyperglycemic condition for 96 hours as mentioned previously. However, the 
last miRNA, miR-146a-5p, was differentially and solely expressed in HRECs under high 
glucose and then treated with ApN. Searching for target genes and pathways for has-miR 
146-5P, showed that it has similar involvement as other differentially expressed miRNAs 
and targets the cytokine-cytokine receptor interaction pathway, chemokine signaling 
pathway, cell adhesion molecules, and diabetes mellitus. Overexpression of VEGF was 
associated with the downregulation of miR-146a-5p whereas miR-146a-5p regulates 
many genes transcript levels including NF-kB and VEGF in diabetic retinopathy (174, 
175). Moreover, diabetic streptozotocin rat’s retinal endothelial cells showed a decrease 
in miR-146a expression which was proven to regulate the expression of fibronectin. 
Increase in the production of extracellular matrix proteins and fibronectin is one of DR 
dysfunctions that are induced by hyperglycemia (176). Therefore, miR-146a injection 
 102 
 
could counteract the high effect of glucose and decrease the level of fibronectin in 
diabetes (177). In a recent study where human retinal endothelial cells were used to study 
the role of miR-146a in attenuating the inflammatory pathways induced by 
hyperglycemia (178). Results indicated that miR-146a decreased the elevation of 
glucose-induced TNF𝛼 and inhibited the activation of NF-𝜅B to protect the retinal cells. 
Therefore, miR-146a could be a potential therapeutic approach for DR targeting TNF𝛼 
and NF-𝜅B inflammatory pathways. Such data could highlight the role of adiponectin in 
ameliorating the HG conditions which pertain to DR pathogenesis. These could include 
inflammatory pathways, adhesion molecules and, angiogenesis as shown in these data.  
The following study has some limitations that could be addressed and improved in 
the future. For example, only IL-6 was assessed as an inflammatory cytokine due to 
limited technical facilities. Moreover, assessment of adhesion molecules like VCAM-1 
and ICAM-1 as well as other antioxidants would strengthen the findings of the study. 
Also, due to limited time and facilities, RT-PCR profiler conducted twice as a screening 
tool, and no P-value was obtained for the expressed genes. Repeating this screening three 
times would give more validated and significant results than just screening once. 
miRNAs identified in the current study need to be validated at qPCR level. Once 
validated, possible target genes of the verified miRNAs could be identified and then and 
conduct Western blots to show a reduction in corresponding protein levels. Also, 
transfecting cells with antagomirs, to block miRNAs; showing that protein expression 
level can be rescued is further validations of the miRNA-gene target connection. 
In conclusion, a total of 14 dysregulated miRNAs in diabetic human retinal 
endothelial cells were identified in this study. MiRNAs targets and pathways were 
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determined using bioinformatics analysis and different databases. It was noticed how 
miRNA could affect multiple genes through different pathways. This, in turn, could a 
potential approach for using miRNAs as therapeutic targets for DR. Adiponectin could 
improve the dysfunction of HREC through different mechanisms through the 
upregulation of the AdipR1, improving the viability and moreover the regulation of mir-
146a  which target different pathways involved in DR genesis. 
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APPENDIX 
 
Appendix A: RT2 Profiler PCR Arrays 
 
Gene list of human endothelial cell biology array. 
 
Angiogenic Growth Factors 
Growth Factors & Receptors: ANG, ANGPT1, ANGPT2, ANPEP, TYMP, FGF1, 
FGF2 (BFGF), FIGF (VEGFD), FLT1 (VEGFR1), JAG1, KDR (VEGFR3), NRP1, 
NRP2, PGF, VEGFA, VEGFB, VEGFC. 
Cell Adhesion Molecules: ADGRB1 (BAI1), COL4A3, CXCL8, NRP1, NRP2. 
Extracellular Matrix (ECM) Molecules: ANGPTL4, F3, PECAM1, PF4, PROK2, 
SERPINE1 (PAI-1), SERPINF1. 
Other Angiogenic Factors: HIF1A, NOS3 (eNOS), SPHK1. 
 
Cytokines: CCL11 (eotaxin), CCL2 (MCP-1), CXCL1 (GRO1, GROa, SCYB1), 
CXCL10 (INP10), CXCL5 (ENA-78, LIX), CXCL6 (GCP-2), CXCL9 (MIG), EDN1, 
IFNA1, IFNG, IL1B, IL6, MDK, TNF. 
 
Growth Factors & Receptors: CTGF, EFNA1, EFNB2, EGF, EPHB4, FGFR3, HGF, 
IGF1, ITGB3, PDGFA, S1PR1, TEK (TIE-2, TIE2), TGFA, TGFB1, TGFB2, TGFBR1 
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(ALK5). 
 
Cell Adhesion Molecules: CCL11 (eotaxin), CCL2 (MCP-1), CDH5, COL18A1, CTGF, 
ENG (EVI-1), ERBB2 (HER-2, NEU), FN1, ITGAV, ITGB3, S1PR1, THBS1 (TSP-1), 
THBS2. 
Extracellular Matrix (ECM) Molecules: LECT1, LEP (leptin), MMP14, MMP2, 
MMP9, PLAU (UPA), PLG, TIMP1, TIMP2, TIMP3. 
Other Angiogenic Factors: AKT1, HPSE, ID1, NOTCH4, PTGS1 (COX1), TIE1. 
Gene list of cell adhesion molecules 
 
Transmembrane Receptors 
CD44, CDH1 (E-Cadherin), HAS1, ICAM1, ITGA1, ITGA2, ITGA3, ITGA4 (CD49D), 
ITGA5, ITGA6, ITGA7, ITGA8, ITGAL, ITGAM, ITGAV, ITGB1, ITGB2, ITGB3, 
ITGB4, ITGB5, MMP14, MMP15, MMP16, NCAM1, PECAM1, SELE, SELL 
(LECAM-1), SELP, SGCE, SPG7, VCAM1. 
 
Cell-Cell Adhesion 
CD44, CDH1 (E-Cadherin), COL11A1, COL14A1, COL6A2, CTNND1, ICAM1, 
ITGA8, VCAM1. 
 
Cell-Extracellular Matrix (ECM) Adhesion 
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ADAMTS13, CD44, ITGA1, ITGA2, ITGA3, ITGA4 (CD49D), ITGA5, ITGA6, 
ITGA7, ITGA8, ITGAL, ITGAM, ITGAV, ITGB1, ITGB2, ITGB3, ITGB4, ITGB5, 
SGCE, SPP1, THBS3. 
Other Cell Adhesion Molecules 
CNTN1, COL12A1, COL15A1, COL16A1, COL5A1, COL6A1, COL7A1, COL8A1, 
VCAN, CTGF, CTNNA1, CTNNB1, CTNND2, FN1, KAL1, LAMA1, LAMA2, 
LAMA3, LAMB1, LAMB3, LAMC1, THBS1 (TSP-1), THBS2, CLEC3B, TNC, VTN. 
 
Extracellular Matrix (ECM) Molecules Basement Membrane Constituents 
COL4A2, COL7A1, LAMA1, LAMA2, LAMA3, LAMB1, LAMB3, LAMC1, SPARC. 
Collagens & ECM Structural Constituents: COL11A1, COL12A1, COL14A1, 
COL15A1, COL16A1, COL1A1, COL4A2, COL5A1, COL6A1, COL6A2, COL7A1, 
COL8A1, FN1, KAL1. 
 
Extracellular Matrix (ECM) Proteases 
ADAMTS1, ADAMTS13, ADAMTS8, MMP1, MMP10, MMP11, MMP12, MMP13, 
MMP14, MMP15, MMP16, MMP2, MMP3, MMP7, MMP8, MMP9, SPG7, TIMP1. 
Extracellular Matrix (ECM) Protease Inhibitors: COL7A1, KAL1, THBS1 (TSP-1), 
TIMP1, TIMP2, TIMP3. 
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Other Extracellular Matrix (ECM) Molecules 
VCAN, CTGF, ECM1, HAS1, SPP1, TGFBI, THBS2, THBS3, CLEC3B, TNC, VTN. 
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Appendix B: Box plot for normalized sequenced data 
 
 
